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Tuberculosis (TB) caused by Mycobacterium tuberculosis (Mtb) kills 1.6 million people 
worldwide every year, and there is an urgent need for targeting host-pathogen interactions 
as a strategy to reduce mycobacterial resistance to current antimicrobials. Non-coding RNAs 
are emerging as important regulators of numerous biological processes and avenues for 
exploitation in host-directed therapeutics. Although long non-coding RNAs (lncRNAs) are 
abundantly expressed in immune cells, their functional role in gene regulation and 
mycobacterial infections remains under-studied. Here, we identify an immunoregulatory, 
lincRNA-MIR99AHG, which is upregulated in macrophages upon IL-4/IL-13 stimulation and 
downregulated after Mtb infection and in active TB patients. To evaluate the functional role 
of lincRNA-MIR99AHG, we employed antisense GapmeR-mediated lncRNA knockdown 
experiments. Knockdown of lincRNA-MIR99AHG with LNA-GapmeRs significantly reduced 
intracellular Mtb growth in mouse and human macrophages and reduced proinflammatory 
cytokine production. In addition, in vivo treatment with MIR99AHG LNA-GapmeRs reduced 
the lung and spleen mycobacterial burden in mice. In vivo LNA-GapmeR treatment 
experiments demonstrated a role of lincRNA-MIR99AHG as a regulator of macrophage 
polarization and a host protective response following Mtb infection. Further, lincRNA-
MIR99AHG translocated to the nucleus and interacts with high affinity to hnRNPA2/B1 
following IL-4/IL-13 stimulation and Mtb infection. We also identify the functional role of 
lncRNA IL7-AS in unstimulated and M1 (IFN-γ) in mouse and human macrophages during Mtb 
infection. In this study we show that IL7-AS is highly induced following Mtb infection. 
Knockdown of IL7-AS with LNA-GapmeRs reduced intracellular Mtb growth in mouse and 
human macrophages. IL7-AS appears to negatively regulate IL-6, IL-1α, IL-1β and IL-12 in Mtb 
infected macrophages. Knockdown of IL7-AS with LNA-GapmeRs does not seem to have a 
significant impact on the mRNA production of IL-7 suggesting that the function if IL7-AS is not 
dependent on IL-7 in cis. We also show that IL7-AS expression is dependent on the NF-κB and 
MAPK signalling pathways in macrophages. We show the relevance of IL7-AS being 
upregulated in active TB patients suggesting that it may play an important role for host-
directed targeting. Therefore, our data show an important role of IL7-AS as a promoter of Mtb 
growth and transcriptional activator of inflammatory genes during Mtb infection. Together, 
these findings identify lincRNA-MIR99AHG and IL7-AS as promoters of Mtb growth and a 
possible target for adjunctive host-directed therapeutics against TB.   
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Chapter 1: Introduction and Literature review 
1.1 Introduction  
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is one of the leading 
infectious diseases in the world [1].  Globally, 1.7 billion people are infected with Mtb and are 
at risk of developing active tuberculosis [1] It is estimated that TB causes more than 1.5 million 
deaths per year with Africa experiencing the second highest burden (24%) [1]. The eight 
countries which contributed the most to the global disease burden included South Africa [1]. 
There is an urgent need to develop new treatment approaches due to the rise of multi-drug 
resistant strains of TB, the amount of time required to complete treatment and some factors 
that cause patients not to complete treatment. South Africa has one of the highest burdens 
of TB cases which may lead to a multi-drug epidemic [2]. Novel anti-TB therapies need to be 
developed as more research identifies important crucial factors that play a role in the 
pathogenesis of TB. There is growing awareness towards host factors and one of the recent 
approaches is to develop host-directed therapy (HDT) [3]. Host directed therapeutics targets 
host responses that Mtb may hijack to induce persistence within the host rather than 
targeting the pathogen directly by conventional antibiotics. Targeting HDT results in a 
reduction in pathology, mycobacterial burden and possible latency that could be achieved by 
targeting and using the same host factors Mtb uses [3]. For countries such as South Africa 
which face an epidemic of multi-drug resistant TB, targeting host factors as therapy is less 
likely to cause multi-drug resistance compared to the FDA-approved drugs. For host-directed 
targets to be effective they must be able to induce a variety of host-pathogen protective 
mechanisms such as the innate signalling pathway, phagosomal maturation, bactericidal 
mechanisms, autophagy, prevent Mtb binding and uptake, phagosomal escape and/or 
detoxification [4]. However, Mtb has evolved mechanisms in which it is able to prevent 
inhibition of phagosomal acidification by inhibition of proton ATPase [5], preventing calcium 
signalling [6] and hindering the fusion machinery of vesicular transport [7]. 
1.2 Background  
Mtb is predominantly transmitted by the respiratory route, and while it is able to cause 
disease in most organs in the body, the most reported and occurring is pulmonary 
tuberculosis [8]. The host immune response against Mtb infection is complex and 
multifaceted. The GENCODE project, with the aim to show all functional importance in human 
DNA, estimates that 2% of the mammalian genome comprises of protein-coding genes while 
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98% is transcribed as non-coding RNAs [9]. Non-coding RNAs (ncRNA) are mainly categorized 
as either short ncRNA (<200 nucleotides) or long ncRNA (>200 nucleotides) [10]. Very little is 
known about long noncoding RNAs (lncRNAs) and their functions. Recent published research 
now shows that lncRNAs play a significant role in many physiological and pathological 
processes [11]. The function of lncRNAs in immune cells is recently emerging [12]. A few 
studies have been conducted to demonstrate lncRNA function in immune cells. For example, 
lincRNA-EPS is an inhibitor of immune response gene (IRG) expression, acting as a regulatory 
checkpoint that is downregulated prior to inducible expression of IRGs [13]. Many other 
lncRNAs including lincRNA-Cox2 [14], THRIL [15], Mirt2 [16], and lnc13 [17] also regulate 
inflammatory genes in myeloid cells.  
 
 
Figure 1.1 Estimated countries with highest TB incidence. Image sourced form WHO [1].  
 
There is very limited work on functionally validated lncRNAs in response to Mtb infection and 
no scientific research/publication of functionally validated lncRNAs in polarised M1 (IFNγ) or 
M2 (IL-4/IL-13) and/or Mtb infected macrophages. Due to the lack of limited research on the 
role of lncRNAs during Mtb infection we sought to identify the functional role of lincRNA-
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MIR99AHG in polarised Mtb-infected macrophages and its prophylactic effect on Mtb- 
infected mice.  
1.3 Long non-coding RNAs 
The activation of the innate and adaptive immune cells cannot be induced without a 
coordinated set of transcriptional and post transcriptional events [18]. During these events 
many protein-coding genes are activated and repressed [18]. A potential host-derived drug 
target which has recently gained awareness is long non-coding RNAs (lncRNA). Both DNA 
strands are generally transcribed, which then gives rise to many various classes of non-coding 
RNAs (ncRNAs) [19]. Approximately 167 150 and 130 558 lncRNA transcripts have been 
identified in humans and mice, respectively [20].  There are many different expression 
patterns of lncRNAs in various cell types, tissues, developmental stages, and context-specific 
manners [21]. This abundant mixture of long and short non-coding RNAs was misunderstood 
in past years as transcriptional noise or junk [22].  
 
Very little is known about lncRNAs although, in comparison with miRNAs, these are generally 
shorter in length, contain fewer albeit longer exons, and are expressed at lower levels [22-
24]. lncRNAs are poorly conserved, with an estimation of only 15% of mouse protein coding 
genes reported to have human homologues, leading to assumption that the many lncRNAs 
are not functional [24-27]. Currently, lncRNAs are arranged according to their position relative 
to protein-coding genes [10]. These include the long intergenic ncRNA (lincRNAs) located 
between protein coding genes, intronic lncRNAs which are transcribed from intronic regions 
in either sense or antisense orientation, antisense lncRNAs which are transcribed across the 
exons of protein coding genes, transcribed pseudogene lncRNAs, bidirectional lncRNAs which 
are located on the opposite strand from a protein coding gene and enhancer RNA (eRNAs), 
which are less than 2 kb in length, these are bidirectionally transcribed from enhancer regions 
[10]. There is increasing research on the function and mechanism of lncRNAs, this includes 
chromatin modification, transcriptional regulation, post transcriptional regulation and gene 
regulation [10]. LncRNAs have been reported to be important regulators of physiological and 
pathological responses [11, 28]. However, their importance in the innate immune response is 
only now becoming prominent. A few studies have been conducted on the functional role of 
lncRNAs in the immune system. This literature review will investigate functions of how 
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lncRNAs regulate the innate immune system specifically during bacterial infection, host-
pathogen interaction, their mechanism of action and how we identified lincRNA-MIR99AHG. 
 
 
Figure 1.2 Classification of lncRNAs based on their genomic location with respect to nearby 
protein-coding genes. Image sourced from Atianand et al. [12]. 
 
FANTOM (Functional Annotation Of the Mammalian genome) is an international research 
consortium developed by RIKEN mainly centred on functional annotation of mammalian 
genomes and characterization of transcriptional regulatory networks. The FANTOM5 
consortium, with over 500 international members from 20 countries, has generated maps of 
human regulatory elements and transcriptional regulatory network models. To attain this 
goal, they used CAGE (Cap Analysis of Gene Expression) sequencing on RNA samples from 
every major human organs, various primary cell types, over 200 cancer cell lines, 30 time 




Using the CAGE approach, 64 lncRNA transcripts that were differentially expressed upon 
cytokine stimulation and/or Mtb infection on BMDMs were identified. The selected lncRNAs 
were either induced upon M1 (IFN-γ), M2 (IL-4, IL-13) or Mtb stimulation. Subsequent RT-
qPCR validation yielded a shortlist of 9 lncRNAs on M1 and M2 polarised macrophages which 
we intend on functionally validating.  Five lncRNAs encoded by the same phylogenetically well 
conserved gene, the MIR99AHG gene, were highly induced by IL-4/IL-13. The analysis of the 
MIR99AHG gene locus showed enrichment and overlapping of H3K4m1, H3K4me3 and 
H3K27ac marks; CTCF and POLII binding on the first exon of those lncRNAs, indicative of an 
active transcription and a potential enhancer-like function. There has been one study 
conducted on MIR99AHG wherein MIR99AHG and MIR100HG have been shown to act as 
ancogenes in acute megakaryoblastic leukaemia [29]. We also chose to functionally validate 
IL7-AS which was highly upregulated upon Mtb infection. There is increasing literature  
describing the functional role of IL7-AS in biological processes [30, 31] but limited research on 
its role during Mtb infection. Due to limited research on the effect of lncRNA regulation in 
polarized macrophages and during Mtb infection, we sought to establish the functional role 
of MIR99AHG and IL7-AS in polarized macrophages and during Mtb infection. 
 
1.4 lncRNA classification and characteristic features 
Approximately 2% of the human genome is transcribed into protein-coding RNAs, the 
remaining 98% is transcribed into non protein-coding RNAs referred to as non-coding RNAs 
(ncRNAs) [32]. These ncRNAs include many types of RNA. Examples include transfer RNAs 
(tRNAs), ribosomal RNAs (rRNAs) and small nuclear RNAs (snRNAs), with well-defined 
functions in various cellular processes [33-36]. There are other various ncRNAs with unknown 
functions and limited information, many of which are considered as lncRNAs [33, 37]. These 
lncRNAs are poorly conserved and are distinguished by their positions respective to the 
protein-coding genes [10, 37, 38]. They have some similarities with protein-coding transcripts; 
in general these lncRNAs are transcribed by the RNA polymerase II and can be capped, 
polyadenylated and spliced [32]. The lncRNAs are either localized in the nucleus or the 
cytoplasm [34].  
 
Currently lncRNAs are classified according to their positions respective to protein coding 
genes [10]. Antisense lncRNAs are transcribed from the opposite strand of a protein-coding 
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gene or a sense strand-derived RNA [19] whereas intronic lncRNAs are transcribed from 
intronic regions of either the sense or antisense strand [10]. The largest group, located 
between protein coding genes, are the intergenic lncRNAs (lincRNAs) [10]. Classes of lncRNAs 
that lack a poly (A) tail include: eRNAs (enhancer RNAs); sno-lncRNAs (snoRNA-related 
lncRNAs); circRNAs (circular RNAs); and ciRNAs (circular intronic RNAs) [39].   
 
1.5 Mechanism of action of lncRNAs 
Long non-coding RNAs (lncRNAs) are known to act via post transcriptional mechanisms by 
targeting splicing, stability, or translation of host mRNAs [4]. Long non-coding RNAs can also 
affect the expression of immune response genes through a variety of mechanisms [6]. It has 
been proposed that the antisense lncRNAs can be classified as mRNA-flanking lncRNA (mf-
lncRNAs), despite their limited or no overlap with protein-coding genes [40]. This group of 
antisense lncRNAs include THRIL [15], PACER [41], lincR-Ccr2-50AS [42], lnc-IL7R [43] and IL1b-
RBT46 [44],  which have been reported to regulate the expression of their neighbouring 
protein-coding gene in cis [10]. They have also been reported to regulate the expression of 
many additional genes in trans  [10]. Many of the reported immune-related lncRNAs, which 




Figure 1.3 Different roles of long non-coding RNAs. Image sourced from Neguembor et al. 
[45]. 
One of the current mechanisms of most immune-related lncRNAs is believed to be through 
protein binding [10]. LncRNAs related to immune responses have been reported to be linked 
to members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family [14, 15] and 
components of chromatin-modifying complexes including the polycomb repressor complex 2 
[46], WD repeat domain 5, a core subunit of the MLL methyltrans-ferase complex [47], and 
the UTX/JMJD3 demethylases [48]. Though the mechanism is not clearly defined, it has been 
suspected that they might act as scaffolds to bring together proteins and/or target these to 
the DNA through base-pairing [28].  
 
1.6 LncRNAs in host–pathogen interactions 
Host lncRNAs produced by many pathogens are known to play significant roles in both the life 
cycle and/or interaction between intracellular pathogens and their host cells [10]. An example 
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of a lncRNA that plays an important role in the interaction between HIV-1 and its host cells is 
NEAT1 [49]. NEAT1 is reported to influence HIV-1 replication by regulating the nuclear-to-
cytoplasmic export of Rev-dependent instability element containing HIV mRNA [49]. Another 
well-studied example is polyadenylated nuclear (PAN) RNA produced by Kaposi’s sarcoma-
associated herpesvirus (KSHV) [48]. PAN RNA controls viral gene expression and inhibits the 
host immune response [48]. The expression of PAN RNA is important in the switch from latent 
to lytic infection [48, 50]. PAN RNA mechanism involves physical interaction with LANA 
(latency associated nuclear antigen) [48]. LANA, a protein, is known to maintain latency by 
binding to the KSHV genome and modulating the dissociation of the protein once the virus is 
activated [48]. Furthermore, PAN RNA also suppresses the expression of host genes that are 
involved in the inflammatory and anti-viral response [48]. Overall, these studies suggest that 
lncRNAs play a significant role of regulating viral and host gene expression.  
1.7 ncRNAs regulate the innate immune system 
The first reported evidence of the role for lncRNAs in the innate immune response was 
reported by Guttman et al. [51] who used the intergenic deposition of epigenetic marks to 
identify 20 lincRNAs induced in LPS stimulated mouse bone marrow-derived dendritic cells 
(BMDCs). Microarray analysis and RNA sequencing have reported the differential lncRNA 
expression following activation by TLR agonists in monocytes, macrophages, dendritic cells, 
and fibroblasts, as well as following viral infection in mouse lungs [14, 15, 52-56]. There is a 
growing body of literature that reports on specific lncRNA involvement in host cell response 
to bacterial infections or stimulation with bacterial compounds. However, the functional role 
of lncRNAs in TB immunity is still very limited.  
 
1.7.1 LincRNA-Cox2 facilitates the induction and repression of gene expression in mouse 
macrophages 
LincRNA-Cox2, located 50 kb downstream from the Cox2 gene, was first identified by [51]. 
This lincRNA was demonstrated to supress the expression of 787 genes in non- stimulated 
BMDMs and induce 713 genes following exposure to palmitoyl-3cysteinyl-seryl-4 (Pam3CSK4) 
[14]. LincRNA-Cox2 and Ptgs2 were induced following exposure to LPS in BMDCs [14]. Gene 
Ontology analysis revealed that these differentially expressed genes were enhanced for genes 
involved in the immune response and included CCL5 and IL-6 [51]. The suppression of lincRNA-
Cox2 was facilitated through interaction with hnRNP-A/B and hnRNP-A2/B1 [14]. Sauvageau 
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et al. [57] reported on the generation of a lincRNA-Cox2 knockout mouse which provides an 
important resource for in vivo studies [57]. In their recent publication of the lincRNA-Cox2 
knockout mice they revealed that lincRNA-Cox2 functions through an enhancer RNA 
mechanism to regulate Ptgs2 levels [58]. They also showed that lincRNA-Cox2 has a trans 
regulatory role controlling many innate immune genes and the locus regulates the expression 
of local and distant genes [58] . 
  
 
Figure 1.4 LncRNA-mediated regulatory circuits in inflammatory response in myeloid cells. 
Image sourced from Atianand et al. [12] 
 
1.7.2 THRIL regulates TNF-α release and global gene expression in human monocytic THP-
1 cells 
Li et al. [15] showed that the expression of THRIL in THP- 1 cells is reduced post Pam3CSK4 
stimulation [15]. Although this effect was indirect and dependent on autocrine/paracrine 
TNFα release, the knockdown of THRIL reduced the expression of 444 genes in unstimulated 
cells and downregulated the differential expression of 317 out of a total of 618 genes post 
Pam3CSK4 stimulation, these include many inflammatory genes such as IL6, CXCL8, CXCL10, 
CCL1, and CSF1 [15]. Similarly, with lincRNA-Cox2, THRIL was shown to interact with hnRNPL 
[15]. This resulted in the complex binding to the TNFα promoter and driving transcription in 
both control and Pam3CSK4-stimulated THP1 macrophages [15].  
 
1.7.3 lincRNA-EPS regulates the expression of immune response genes in macrophages.  
Using RNA sequencing, Atianand et al. [13] and colleagues identified lncRNAs that were 
downregulated in macrophages following LPS stimulation. One of the downregulated lncRNAs 
was lincRNA-EPS which was initially described as a regulator for erythrocyte differentiation 
[59]. lincRNA-EPS inhibits the expression of immune response genes (IRG) in both resting and 
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LPS stimulated macrophages [13]. Gain-of-function and rescue studies further confirmed 
lincRNA-EPS as a repressor of IRG expression [13]. The mechanism of lincRNA-EPS showed 
that it associates with chromatin and interacts with protein coding gene, hnRNPL, to inhibit 
the nucleosome positioning and repress IRGs [13]. lincRNA-EPS-/- mice had increased 
susceptibility to LPS challenge in vivo [13].     
 
1.7.4 lncRNA Mirt2 is a negative regulator of inflammation 
In this study Du et al. [16] and colleagues performed a microarray analysis in primary cultured 
peritoneal macrophages from C57BL/6 mice to identify lncRNAs that are involved in the 
innate immune response.  Mirt2 was among the highly induced lncRNAs by LPS stimulation 
[16]. They further show that Mirt2 acts as a barrier to inhibit uncontrollable induction of 
inflammation, and is a potential regulator of macrophage polarization [16]. Mirt2 was shown 
to associate with, and also reduce Lys63 (K63)-linked ubiquination of TRAF6 [16]. This 
association leads to the inhibition of NF-κB and MAPK pathways thus limiting the production 
of proinflammatory cytokines [16]. 
 
1.8 Functionally validated lncRNAs during Mtb infection 
1.8.1 lncRNA-CD244 epigenetically controls CD8+ T-cell immune responses in tuberculosis 
infection. 
CD4+ T cells, CD8+ T cells, and γδ T cells play important roles in establishing an adaptive 
immune response against Mtb infection [34, 60, 61]. CD244 is a costimulatory receptor 
important in the  regulation of immune functions of Natural Killer (NK) cells [62]. It  provides 
a negative signal that inhibits the activation signal provided by TCR engagement in CD8+ T 
cells [63]. There is not much known on the molecular mechanism and consequence for CD244 
regulation of T-cell effector functions during active TB infection. Wang et al. [64] examined 
whether CD244 signalling regulates T-cell effector function, how it affects homeostasis and 
host defence against Mtb infection [64]. Human lncRNA microarray and hierarchical clustering 
analyses were used to differentiate lncRNA expression in CD244+ CD8+ T cells and CD244- CD8+ 
T cells [64].The microarray analysis identified highly expressed groups of lncRNAs 
differentially expressed in CD244+ CD8+ T cells [64]. They showed that lncRNA-CD244 acts as 
an epigenetic regulator of IFNγ and TNF-α in production in CD8+ T cells and impacts CD8+ T-




1.8.2 The antituberculosis effect of lncRNA NEAT1  
The differential expression and importance of NEAT1 was analysed in active tuberculosis 
patients. PBMCs from patients with tuberculosis had increased expression of NEAT1 [65].  
NEAT1 was markedly increased after Mtb infection in THP-1 macrophages [65], however 
silencing of NEAT1 resulted in enhanced intracellular growth of Mtb and reduced IL-6 levels 
[65]. 
 
1.8.3 The role of lncRNA PCED1B-AS1 
The authors examined the functional role of lncRNA PCED1B-AS1 on macrophage apoptosis 
and autophagy [66]. LncRNA PCED1B-AS1 expression was downregulated in patients with 
active tuberculosis [66]. Knockdown of lncRNA PCED1B-AS1 reduced macrophage apoptosis 
and promoted autophagy [66]. It was also observed that lncRNA PCED1B-AS1 serves as a 
sponge for miR-155 indicating that lncRNA PCED1B-AS1 modulated macrophage apoptosis 
and autophagy by targeting miR-155 in active TB patients [66].  
 
1.9 Functionally validated lncRNAs in Mycobacterium bovis BCG 
1.9.1 LncRNA MEG3 eradicates mycobacteria in macrophages via autophagy 
MEG3 was preselected due to its known role in immune related functions in cancer [67]. 
Human macrophages were stimulated with Mycobacterium bovis BCG and the expression of 
MEG3 was analysed at early time points [68]. Using microarray analysis Pawar et al. [68] and 
colleagues showed the downregulation of MEG3 after Mtb BCG infection. MEG3 was linked 
to mTOR and PI3K-AKT signalling pathways therefore affecting the regulation of autophagy 
[68]. IFN-γ induced autophagy further reducing MEG3 and knockdown of MEG3 in 
macrophages resulted in autophagy and increased clearance of intracellular M. bovis BCG 
[68].  
 
1.9.2 lincRNA-Cox2 induces intracellular mycobacterium killing in macrophages 
LincRNA-Cox2 is upregulated by BCG infection in a time and MOI dependent manner [69]. 
Knockdown of lincRNA-Cox2 reduces mycobacterium intracellular growth by induction of 
proinflammatory cytokines such as TNFα, IL-6, IL-12 [69]. The suppression of intracellular 
growth is also through inhibition of nitric oxide production [69]. Nitric oxide production is 




1.10 Expression profiles of lncRNAs in immune cells infected with Mtb 
Macrophages are well known in their important role in the controlling and clearing of 
Mycobacterium tuberculosis (Mtb) and also serve as host for Mtb [70]. Microarray analysis 
was used to investigate the expression profiles of lncRNAs and mRNAs in human macrophages 
infected with avirulent strains H37Rv and H37Ra [71]. The microarray analysis revealed 
differentially expressed lncRNAs [71]. Two lncRNAs, MIR394HG V1 and MIR394HG V2, were 
identified as novel candidates for diagnostic markers for tuberculosis [71].  
 
1.11 Differential expression of lncRNAs in serum, active TB vs healthy or latent individuals 
Expression profiles of lncRNAs from PBMCs derived from healthy donors and donors with 
MDR-TB and drug sensitive TB (DS-TB) were analysed using the microarray assay [72]. A total 
of 1, 429 and 2, 040 lncRNAs were downregulated in MDR-TB and DS-TB groups, respectively 
[72].  The expression profile of long noncoding RNAS were investigated in serum using 
microarray analysis [73]. A total of 163 lncRNAs were upregulated and 348 were 
downregulated. Using Gene ontology (GO), Kyoto Encyclopedia of Genes and Genomes 
(KEGG) analyses they show that the functions of the differentially expressed lncRNAs were 
mainly associated with the regulation of alpha-beta T cell activation and T cell receptor 
signalling pathway [73]. Expression profiles of lncRNAs in CD4+ T cells from latent and active 
TB donors were analysed using the microarray assay [74]. Compared to the healthy controls 
there was a total of 449 and 461 lncRNAs that were downregulated in LTBI, while 1, 113 and 
1, 490 lncRNAs were downregulated in active TB group [74] 
 
1.12 LncRNA interaction 
1.12.1 LncRNAs and gene interaction 
It has been reported that lncRNAs play a role in the epigenetic regulation of gene expression 
[75-77], and recent studies have proposed an integrated mechanism of action [78]. Protein 
complexes involved in chromosome modifications are recruited by lncRNAs directly or 
indirectly, which also results in epigenetic regulation [79]. Depending on the relative 
positioning between lncRNAs and their target genes, the mechanism by which lncRNAs 
regulate their target genes can be considered either cis [80] or trans [81]. LncRNAs that act in 
cis can regulate gene expression and/or chromatin state of neighbouring genes and those that 
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act in trans are able to perform a variety of functions throughout the cell. In lncRNAs that 
have been reported to regulate target genes in cis, it has been shown that RNAs can form a 
nuclear complex that is linked to silenced genes [78]. Gene silencing is achieved through 
binding of lncRNAs to epigenetic modifiers [82]. An example is the HOTAIR lncRNA which 
inhibits gene expression in trans with Polycomb Repressive Complex (PRC) to regulate 
transcriptional inhibition of the HOXD locus [83]. 
 
1.12.2 lncRNAs and protein interaction 
There is vast research showing how long non-coding RNAs  function with their binding 
proteins [42]. Experimental methods such as mass spectrometry analysis followed by RNA 
immunoprecipitation have been used to identify lncRNA binding proteins [42]. A 
computational method called CatRAPID has been recently developed to predict RNA-protein 
interactions in the Xist network [84]. lncPro has been introduced as a new method to predict 
the interaction between lncRNAs and proteins [42]. Matrix multiplication is also used to score 
each RNA-protein pair as a measure of interaction within the pair  [42]. This method 
distinguishes between interacting and non-interacting RNA-protein pair and predicts RNA-
protein interactions within a given multiplex [42]. It was found that lncRNAs interacted with 
nuclear proteins and RNA-binding proteins when this method was applied on all human 
proteins [42]. 
 
1.12.3 lncRNAs and disease association 
More and more studies are reporting that lncRNAs are implicated in a wide range of human 
diseases [41]. The dysregulation of lncRNAs has been reported to be the main cause of 
complex human disease processes [78]. ANRIL has been associated with coronary disease, 
type 2 diabetes and many other types of cancer [41]. HOTAIR expression is increased to over 
200-fold in breast cancer metastases using qPCR [85]. MALAT-1 is reported to be associated 
with metastases in NSCLC (non-small-cell lung carcinoma) patients by qPCR [86]. With regards 
to Alzheimeir’s disease, BCAE1-AS was shown to regulate BACE1 and in driving pathology [87]. 
It is important to analyse the available lncRNA-disease associations and predict potential 
lncRNA-disease associations in human [41]. These analysis will help in understanding 
molecular mechanisms of human diseases and help identify biomarkers for disease diagnosis, 
treatment and prevention at lncRNA level [41]. 
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1.13 lncRNA bioinformatics 
1.13.1 LncRNAs secondary and tertiary structures 
To understand the function of lncRNAs it is very important to study their structures and the 
interaction between their structure and sequence [78]. RNA has a unique ability to form 
secondary and tertiary folds [88]. The structural flexibility of RNA allows it to perform 
organizational, catalytic and regulatory functions [52]. Finding functional annotation of 
transcriptomes based on RNA structure has now become possible [89]. Due to the increasing 
number of lncRNAs discovered, powerful computational methods to predict RNA structure is 
necessary [78]. There have been a few structure prediction methods reported for non-coding 
RNAs [78]. 
  
1.13.2 Computational prediction of ncRNA secondary structure 
The folding process of the majority of RNA molecules represents a transition between 
secondary and tertiary structure [90]. Finding the secondary fold of RNA is the initial step in 
finding out more about the functions of ncRNAs [88]. There have been a few methods that 
have been proposed to predict RNA secondary structure [78]. These methods are based on 
two different ideas namely the sequence alignments and the minimum free energy model 
[89]. MARNA, one of the methods, is a non-probabilistic approach which performs pairwise 
alignments considering the primary and tertiary structures [78]. The model folds sequences 
using free energy and then provides a structural alignment among a set of homologous 
sequences [78]. When the conservative sequence regions are visible, MARNA can predict the 
RNA secondary structure [78]. The total length of sequences analysed by this model cannot 
be longer than 10, 000 nucleotides [78]. Pfold is based on KH-99 algorithm which combines 
the evolutionary information and a probabilistic structure [78]. This model can accommodate 
a large number of sequences and able to predict a secondary structure when long sequences 
and large homologous sequences need to be analysed [78].  
 
1.13.3 Computational prediction of ncRNA tertiary structure   
The formation of specific tertiary structures is important for the functioning of ncRNAs in 
many biological processes [91]. RNAs can change their tertiary structures allowing them to 
interact with other RNAs, ligands and proteins or themselves [89]. 3dRNA is a method for 
rapid and automated building of RNA tertiary structure [78]. This method can find RNA 
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tertiary structural templates from different RNA families [78]. 3dRNA is not limited to 
predicting tertiary structure and small RNA molecules and or those with simple topology [78]. 
It can predict for RNA molecules with a large size and complex topology [78].  
 
1.14 The role of lincRNA-MIR99AHG in cancer 
1.14.1 MIR99AHG and MIR100HG act as oncogenes in acute megakaryoblastic leukemia 
(AMKL) 
MIR99AHG is transcribed as a polycistronic primary transcript that produces a spliced long 
intergenic noncoding RNA and three intronic miRNAs: MIR99A, MIR125B2 and LET7C [29]. 
The lincRNA-MIR99AHG has a role in cell proliferation and differentiation [29]. However, the 
role of the lncRNA host genes in this ncRNA ensemble remained indefinable [29]. The function 
of MIR99AHG was characterized and a unique role of MIR99AHG was validated during 
hematopoiesis and the pathogenesis of acute megakaryoblastic leukemia (AMKL) [29]. 
MIR99AHG and MIR100HG are highly expressed in AMKL blasts [29]. The transcripts of these 
lncRNAs were mainly located in the nucleus and their expression correlated with the 
corresponding miRNA clusters. Knockdown of both these lncRNAs restrained leukemic growth 
of AMKL cell lines and primary patient samples [29]. Ectopic expression of MIR99AHG 
interfered with hematopoetic lineage decisions and increased the proliferation of immature 
erythroid progenitor cells [29]. 
 
1.15 Possible proximal genes adjacent to MIR99AHG gene 
1.15.1 Cxadr 
The coxsackie B virus and adenovirus receptor (CAR), located downstream of MIR99AHG, is a 
member of the immunoglobulin superfamily [92]. CAR is known to play a pivotal role for the 
entry of both coxsackie B viruses and adenoviruses in to host cells [93]. In addition to viral 
infection it also plays a role in maintenance of the junction adhesion complex in polarized 
epithelia and modulation of cellular growth properties [94]. In a publication by Giaginis et al. 
[93] and colleagues they revealed fort the first time the expression of CAR from patients with 
endometrial adenocarcinoma. CAR appeared to regulate the proliferation and characteristics 
of cancer cells thus its expression could be considered of possible clinical significance for gene 





Little is known about the molecular mechanism that controls downstream signalling from the 
IL-17R complex [95]. To understand the regulatory mechanism of this process, Zhong et al. 
[96] co-expressed various deubiquitinating enzymes with an NF-kB luciferase reporter 
construct and examined the reporter activity upon IL-17A stimulation. The assay revealed that 
the overexpression of the USP25, located upstream of MIR99AHG, significantly and 
specifically inhibited IL-17A- but not TNF-α-mediated NF-κB activation and the expression of 
inflammatory mediators [96]. USP25 binds to and deubiquitinates TRAF5 and TRAF6, thereby 
reducing NF-kB and MAPK signal transduction downstream of the IL-17R complex [96]. USP25-
deficient mice displayed an enhanced IL-17A mediated inflammatory response when 
challenged with IL-17A in vivo or when subjected to IL-17A-related airway inflammation or 
experimental allergic encephalomyelitis (EAE) [96]. These findings demonstrate the 




In a study by [97], higher expression of miR-155 and miR-155* was observed in stimulated 
PBMCs of active tuberculosis patients as compared to unstimulated. Very recently, specific 
secretory M. tuberculosis antigen, ESAT-6 was also found to play a key role in miR-155 
induction and its subsequent effects on Bach1 and SHIP1 repression [98]. It is known that 
Bach1 is a transcriptional repressor of haem oxygenase-1 and (HO-1) which is a documented 
activator of the M. tuberculosis dormancy, thereby favouring M. tuberculosis survival within 
mouse macrophages; whereas SHIP1 inhibits the activation of the serine/threonine kinase 
AKT (required for M. tuberculosis survival) [99]. Although Bach1 is located very far 
downstream of the MIR99AHG host gene, an interaction between this transcription factor 
and MIR99AHG was found in the human embryonic stem cell (ENCODE resource) [96].  Our 
group recently showed that Bach1 is a target for miR-143 and miR-365 which are both highly 
upregulated by Mtb infection [100]. 
 
1.15.4 Btg3 
Btg3 is a member of the B-cell translocation gene (BTG) of ErbB2 gene family [101]. Btg3 is 
thought to be a negative regulator of the cell cycle and it has been shown that its anti-
proliferative action through inhibition of the transcription factor, E2F1 [102]. It has also been 
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shown that Btg3 is associated with the inhibition of Src tyrosine kinase [103]. Other studies 
have shown that Btg3 is a candidate tumor suppressor gene in human non-small lung cancer 
cell and oral squamous cell carcinomas [104]. In a study by Majid et al. [101], Btg3 gene was 
shown to be transcriptionally downregulated in renal cell carcinoma and that its mechanism 
of inactivation is through promoter hypermethylation.  
1.16 Host-directed therapy as adjunct therapy 
Host-directed therapies (HDT) are a promising and new therapeutic approach for treating 
tuberculosis. The use of HDTs is intended to increase the treatment of TB by 
immunomodulation and/or immune augmentation [105]. Therefore, HDTs are very important 
in achieving the 2035 WHO End TB goals [106]. Adjunctive HDT have the potential to shorten 
TB treatment duration, prevent antibiotic resistance and reduce lung injury by promoting 
autophagy, antimicrobial production and other macrophage effector mechanisms [3, 107].  
So far, some HDTs have already been tested preclinical stages. Corticosteroids have been used 
as adjunctive therapy for many inflammatory and disease states [108, 109]. The rationale for 
using corticosteroids in active TB disease mechanistically involves modulation of 
inflammatory and apoptotic gene transcription pathways [110]. Corticosteroids as 
immunoadjuvants to standard TB treatments has proven to be useful in several studies 
including an HIV/TB coinfection framework [111-114]. Another promising candidate for host-
adjunctive therapy for improving TB treatment is metformin. Metformin, an antidiabetic drug, 
has been shown to reduce the intracellular growth of Mtb in an AMPK dependent manner 
[115]. In two separate human cohorts, metformin has been shown to improve the control of 
Mtb and decreased disease severity [115]. The use of metformin in Mtb infected mice 
resulted in improved lung pathology, reduced chronic inflammation and enhanced the 
efficacy of conventional TB drugs [115]. Statins which are widely used to lower cholesterol 
levels, have broad anti-inflammatory and immunomodulatory activities [3, 116]. Statin 
treatment has shown potent adjunctive activity in a TB mouse model and mouse model of 
human-like necrotic TB lung granulomas [116]. Statin treatment and subsequent Mtb 
infection in mice resulted in increased host protection, reduced mycobacterial burden in the 
lungs, decreased dissemination and reduced pulmonary histopathology [117]. There are two 
clinical trials currently testing statins as adjunctive therapy for TB. Our research group is 
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currently involved in a clinical trial that will test atorvastatin in reducing inflammation after 
TB treatment completion.  
 
Many HDT approaches that have gained considerable research interest as adjunct to 
antibiotic-based anti-TB treatments include HDT targeting vitamin D pathway, HDT targeting 
autophagy, HDT targeting inflammatory response and HDT targeting cell-mediated immunity. 
A recent clinical study showed that co-treatment with phenylbutarate (PBA) and vitamin D3 
as an adjunct to standard chemotherapy reduces Mtb growth in MDMs and increases clinical 
recovery compared to the placebo group [118]. Carbamazepine drugs have been shown to 
stimulate autophagy through inositol triphosphate (IP3) depletion and AMP- activated protein 
kinase activation and kill intracellular Mtb in macrophages [119]. In addition, carbamazepine 
treatment without ant-TB drugs reduced MDR-TB burden in lungs and spleen in mice [119]. 
Recently the first therapeutic RNA-based oligonucleotide was approved by the FDA and 
promises to be growing as many biopharmaceutical companies are developing RNA 
interference (RNAi)-based and RNA-based antisense oligonucleotide therapies [120]. The 
potential of using lncRNAs and miRNAs as adjunctive HDT is a topic that is gaining momentum 
especially in the context of infections and diseases. A handful miRNA-targeting drugs have 
entered into clinical trials targeting different diseases. [120] 
1.17 Antisense oligonucleotide delivery  
ASOs are oligonucleotides that function through the RNA interference (RNAi) pathway and  
inhibit mRNA translation [121, 122]. ASOs main aim is to inhibit a molecular target or RNA by 
induction of RNAse H endonuclease activity that binds the RNA-DNA heteroduplex with a 
substantial reduction of the target gene translation [123]. A different mechanism of action is 
through reduction of 5’ cap formation, splice switching, and steric hindrance of ribosomal 
activity [121, 124, 125]. When developing ASOs it is  very important to take into account off 
targets-effects and cytotoxicity [126]. The side effects of ASOs can be dependent on 
sequences and ASO backbone chemistry [126]. To avoid ASOs binding to non-targets, it is very 
important that the secondary and tertiary structures be taken into account to minimize wrong 
cleavage [127-129]. Most GapmeR ASOs are phosporothioated, meaning they are easily taken 
up thus limiting their bioavailability [130, 131]. Their chemical solubility does not affect the 
RNAse H activity or its solubility meaning they can easily be administered by different routes 
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(subcutaneous, intravenous, topical or rectal) [123].  Delivery of ASOs include naked delivery 
for localized treatments [132] , inhalation for pulmonary disease [133], transdermally for skin 
conditions [134] or in combination with other drugs [126].  
1.18 FDA approved ASOs and ASOs in clinical trials 
A few ASOs have been approved by the FDA. Formivirsen is an FDA approved compound 
administered intravenously to treat cytomegalovirus-induced retinitis [135]. Mipomersen is 
administered subcutaneously, for the treatment of homozygous familial 
hypercholesterolemia in the  USA [136]. Eteplirsen, administered intrathecaly is used to treat 
Duchene muscular dystrophy [137]. Nursinersen, a recently approved FDA ASO used to treat 
spinal muscular atrophy, is administered intrathecaly [138]. Defibrotide is a compound 
administered intravenously, used to treat severe hepatic veno-occlusive disease [139].  
 
There are a number of ASOs that are currently under trial. These compounds include NF-kB 
ASO has only been tested in murine models and despite encouraging results there is no 
available data in IBD patients [140]. Smad7 also known as mongersen ASO has been 
formulated to treat active Crohn’s disease patients [141] and the phase III trial has been 
suspended due to reported lack of efficacy of mongersen. Nursinersen is also being clinically 
tested for amyotrophic lateral sclerosis (ALS), Huntington’s disease and cerebellar ataxis, 
however delivery of ASOs remains a key challenge for translational success, especially for 
chronic diseases [137] 
1.19 Research problem and focus 
TB is known to hijack the host’s immune response in the macrophages so it can persist and 
survive. Our research focus is to explore host factors such as lncRNAs and pathways that are 
overturned by Mtb to increase its persistence and survival within the host’s macrophages. 
Host-factor targeting in macrophages is of primary concern because this is the area where 
Mtb initiates infection and develops persistence. This in turn will potentially affect the success 
of future target-based drugs directly. Our research group has already identified differentially 
expressed lncRNAs in M1 (IFNγ) and M2 (IL-4/IL-13) activated macrophages [142]. This study 
will enable the identification of new potential targets and may offer interesting opportunities 




The aim of this study is to functionally validate lincRNA-MIR99AHG and validate its interacting 
partner in polarized and/or Mtb-infected macrophages using chemically engineered 
antisense oligonucleotides (GapmeRs).  
1. 20.1 The objectives of the study: 
1. Investigate the function of lincRNA-MIR99AHG and its target genes using chemically 
engineered antisense oligonucleotides (GapmeRs). 
 
2. Predict lincRNA-MIR99AHG potential targets and interacting partners in polarized and 
Mtb-infected murine and human macrophages. 
1.21 Hypothesis 
Mtb hijacks host lincRNA-MIR99AHG to promote its intracellular survival in macrophages.   
 
Chapter 2: Materials and Methods 
2.1 Materials  
All general reagents were purchased from either of the following suppliers: Merck Chemicals 
(Pty) Ltd.; Gibco Life Technologies; Corning, Invitrogen Life Technologies, Roche, and Sigma 
Aldrich. Molecular biology reagents were purchased from ThermoScientific, BD Bioeciences 
and Fermentas Life Sciences. See Appendix for reagents for all experiments. 
2.2 Methods 
2.2.1 Ethics Statement 
The BALB/c mouse strain were bred and housed in specific pathogen-free conditions and all 
animal procedures were performed in compliance with the standards of practice for 
laboratory animal procedures set by the Animal Research Ethics Committee, Faculty of Health 
Sciences, University of Cape Town, Cape Town, South Africa (Ethics approval Ref 015/037). 
The recruitment of healthy volunteers for this study was approved by the Human Ethics 
Committee, Faculty of Health Sciences, University of Cape Town, Cape Town (HREC Ref 
Number: 635/2015).  Inclusion criteria were as follows: age 18-50 years, both sexes, no history 
of TB, no contact with TB patients, HIV negative, sputum smear-negative, non-smokers, no 
chronic alcoholism, normal chest x-rays, no chronic disease, not receiving immunosuppressive 
therapy, IGRA negative and absence of other pulmonary diseases. The participants who did 
not meet the above criteria, did not consent to signing the information consent form or to 




2.2.2 Generation of Bone Marrow-Derived Macrophages (BMDMs)  
Bone marrow-derived macrophages were generated from 8-11 weeks old male BALB/c mice. 
The mice were sacrificed using halothane  and death was confirmed by cervical dislocation, 
and their femur bones were flushed using plain Dulbecco’s modified Eagle’s medium (DMEM) 
(Gibco, Invitrogen Corporation, Carlsbad, CA, USA) to collect (centrifugation: 1200 rpm; 4°C; 
10 minutes) bone marrow cells. The cells were seeded in sterile 100 mm CORNING plates (14 
x 106 cells/ml) and incubated (37°C; 5% CO2; 70% RH) for 10 days in PLUTZNIK media (DMEM 
containing 10% Foetal Calf Serum, 5% horse serum, 2mM L-glutamine, 1mM Na-pyruvate, 
0.1mM 2-beta-Mercaptoethanol, 30% L929 cell-conditioned medium, 100U/ml penicillin G, 
100μg/ml streptomycin) to allow for their differentiation into BMDMs. On day 10, the 
adherent cells were lifted using 4mg/ml Lidocaine EDTA solution and gentle scrapping, 
thereafter, washed twice with DMEM (containing 10% FCS, 100U/ml penicillin G, 100 μg/ml 
streptomycin) to remove residual M-CSF (present in the L929 conditioned medium). The 
BMDMs were seeded at 2-3 x 106 cells/well, 5x105cells/well and 1x105 cells/well in 6, 24 and 
96-well Nunc plates respectively and incubated (37°C; 5% CO2; 70% RH) overnight before 
performing downstream experiments. 
 
2.2.3 Generation of peripheral blood mononuclear cells (PBMCs) and monocyte-derived 
macrophages (MDMs)  
PBMCs were isolated using Histopaque®-10771 (Sigma-Aldrich Biotechnology LP and Sigma-
Aldrich Co., St Louis, MO) density gradient centrifugation. Blood was collected in VACUETTE® 
K3E blood collection tubes (Greiner Bio-one, GmbH, Germany), transferred to 50 ml Falcon 
tubes and diluted 1:2 with isotonic phosphate buffered saline (PBS) solution pH 7.4. 30 ml of 
diluted blood was transferred to 50 ml LeucosepTM 227290 tubes (Greiner Bio-one, GmbH, 
Germany) loaded beforehand with 15 ml Histopaque® solution as per the manufacturer 
instructions. The tubes were centrifuged at 1000 x g (2229 rpm) for 25 min (acceleration: 9; 
deceleration: 0) using an Eppendorf® 5810R centrifuge (A-4-81 Rotor, radius 18 cm).  Plasma 
was discarded and buffy coat (lymphocytes / PBMCs) layer was harvested into a fresh 50 ml 
Falcon tube. The buffy coat was washed 3 times with 50 ml PBS solution pH 7.4 and spun at 
250 x g for 10 min (acceleration 9, deceleration 5). PBMCs were re-suspended in 2 -5 ml 
complete growth medium (RPMI 1640 medium supplemented with 10% FCS, 2 mM L-
glutamine and 1% penicillin G /streptomycin. All purchased from Life Technologies™, 
Carlsbad, CA, USA).  PBMCs were plated at 1 x 105 cells per 96-well tissue culture plates 
(Corning Costar®, Cambridge, MA) in complete growth medium for downstream bacterial 
burden experiments. 
For the generation of MDMs, PBMCs were plated in 6-/12-/96-well tissue culture plates 
(Corning Costar®, Cambridge, MA) at a density of 20/10/1 x 106 cells per well respectively and 
incubated (37°C; 5% CO2; 70% RH) for 2 hours to allow monocytes to adhere. Non-adherent 
cells were discarded, and adherent monocytes were given a gentle wash with PBS then 
incubated in X-VIVO™ 15 serum free hematopoietic medium (supplemented with 1% 
penicillin G/streptomycin) for 7 days to allow for the differentiation of monocytes into MDMs. 
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X-VIVO™ 15 serum free hematopoietic medium was changed on day 4. On day 7, X-VIVO™ 15 
was removed, MDMs washed once with PBS and complete growth medium added for 
downstream experiments. MDMs purity was assessed by fluorescence-activated cell sorting 
(FACS) analysis using a PE–labeled anti-CD11b; PerCP–labeled anti-HLA-DR; FITC–labeled anti-
CD14   and APC–labeled anti-CD3 monoclonal antibodies (All purchased from BD 
BiosciencesTM CA, USA). MDMs purity exceeded 95%. 
 
2.2.4 Culture of RAW264.7 murine macrophage cell line  
The murine macrophage cell line RAW264.7 were purchased from ATTC. The cells were 
cultured in an incubator (37°C; 5% CO2; 70% RH) using DMEM medium supplemented with 
10% Foetal Calf Serum, 4mM glutamine and penicillin/streptomycin (All purchased from Life 
Technologies™, Carlsbad, CA, USA). 
 
2.2.5 Transfection of BMDMs and MDMs 
MIR-99AHG MiRCURY LNA™ (Exiqon™/Qiagen, Germany) were diluted in Opti-Mem medium 
(Life Technologies™) and mixed in a 1:1 ratio with Lipofectamine 3000 (Life Technologies™). 
Cells were transfected with 25nM of the GapmeR: lipofectamine solution per well for 48 
hours, depending on the downstream experiments.  
 
2.2.6 Stimulation and Mycobacterium tuberculosis infection of BMDMs and MDMs 
Macrophages were stimulated with recombinant mouse (100 units/ml) or recombinant 
human (10 ng/ml) IL-4, IL-13 or a combination of IL-4 and IL-13 (IL-4/13) (BD Bio-sciences). At 
24 hours post-stimulation macrophages were infected with Mtb strain HN878 (clinical 
hypervirulent strain) at a multiplicity of infection (MOI) of 2 bacilli: 1 cell (2:1). After 4 hours, 
the supernatant was removed and fresh DMEM containing 10% FCS, 100U/ml penicillin G, 
100μg/ml streptomycin, 10ug/ml Gentamicin with or without stimulants was added to 
remove extracellular bacteria. Two hours later, the medium was replaced with DMEM 
containing 10% FCS with or without stimulants. Included in an individual experiment, BMDMs 
were also infected with the laboratory strain Mtb H37Rv, HN37Ra and BCG for comparison of 
host response to the clinical hypervirulent Mtb strain HN878. 
 
2.2.7 RNA Extraction 
Cells were lysed in Qiazol (Qiagen, Germany) at different time point’s post-transfection/-
stimulation/-infection and lysates were stored at -80°C. Total RNA was isolated from the 
lysate using miRNeasy Mini kit (Qiagen, Germany) according to the manufacturer’s 
instructions. RNA quantity and purity were measured using the ND-1000 NanoDrop 




2.2.8 cDNA Synthesis and RT-qPCR 
For protein coding gene expression analysis, 100 ng total RNA was reverse-transcribed into 
cDNA using Transcriptor First Strand cDNA Synthesis Kit (Roche, Germany) according to the 
manufacturer’s instructions. Quantitative real-time PCR (RT-qPCR) was performed using 
LightCycler® 480 SYBR Green I Master (Roche, Germany) and gene-specific primers (IDT, CA, 
USA). Fold change in gene expression was calculated by the ΔΔCt method and normalized to 
Hprt1 which was used as internal control. The non-stimulated 0 hour sample was set to 1. 
With regard to miRNAs, total RNA was diluted to 5ng/µl before cDNA was synthesised using 
miRCURY™ LNA MicroRNA PCR System First-Strand cDNA Synthesis Kit (Exiqon, Denmark) as 
per the manufacturer’s instructions. qPCR was performed using miRCURY LNA™ Universal RT 
microRNA PCR New ExiLENT SYBR® Green Master Mix and microRNA LNA™ PCR primer sets 
for MIR99HG and HPRT as internal control (Exiqon, Denmark) in a Roche 480 Lightcycler 
(Roche, Germany). Fold expression was calculated using the ΔΔCt method with non-
stimulated 0hr sample set as 1 (calibrator). Protein coding gene, lncRNA and microRNA qPCR 
primer sequences and PCR run conditions are listed in supplementary table 1. 
   
2.2.9 Bacterial Burden Determination  
At 24- and 48-hours post-infection, supernatant was removed from Mtb-infected 
macrophages and stored at -80ᵒC for analysis of cytokine production. Cells were lysed at 4- 
and 24-hours post infection in Triton X-100 and serial dilutions were plated on Middlebrook 
7H10 agar plates and incubated for 15 days at 37°C in 5% CO2. Colony forming Units (CFUs) 
were enumerated to determine bacterial burden. 
 
2.2.10 Cytokine Production 
Cytokine production was measured by enzyme-linked immunosorbent assay (ELISA) using 
ELISA development reagents (R&D systems, USA). Culture supernatants were diluted 2, 3 and 
6 folds. Data was acquired using Versamax™ Tunable microplate reader with Softmax Pro 
v6.3. (Avantor®, US). 
 
2.2.11 Griess reagent assay 
Cultured supernatants were collected to measure protein levels of nitrite, which correlates to 
nitric oxide (NO) production, by Griess reagents prepared in the lab. Read out was acquired 
using VersamaTM Tumble microplate reader with Softmax Pro v6.3 (Avantor®, US). 
 
2.2.12 Arginase assay 
Cells were lysed with Triton-X100 to measure Arginase activity with reagents prepared in the 





2.2.13 RNA pull-down assay  
Biotin-labelled lncRNA-MIR99AHG were transcribed with biotin RNA Lbeling mix and T7 RNA 
polymerase (Promega), treated with RNase-free DNase I (Promega), and purified using 
RNeasy Mini Kit (Qiagen). Biotin-labeled lncRNA-MIR99AHG was mixed and incubated with 
nuclear extracts of BMDMs. Streptavidin-conjugated magnetic beads (Invitrogen) were added 
to each binding reaction and further incubated. Beads were washed thoroughly. Then the 
retrieved proteins were detected by Western blot. 
Mass Spectrometry analysis a specific band present in the experimental lane will be extracted 
(corresponding region in the control lane will also be extracted). Gel pieces will be digested 
with trypsin and 10% of the peptides will be injected onto a C18 spray tip and eluted into the 
Orbitrap and analysed with a 35 minutes collision induced dissociated method. 
 
2.2.14 RNA Immunoprecipitation (RIP) 
HnRNPA2/B1 experiments were performed in nuclear extracts isolated from IL-4/IL-13 
stimulated and/or Mtb infected BMDMs formaldehyde cross-linked conditions. Assays were 
performed as described in the Novex IP kit protocol (10007D) except that cells were 
crosslinked with 1% formaldehyde for 20 min. Nuclear extracts were precleared with protein 
G beads for 2 hours at 4oC and then incubated with control rabbit IgG or anti-hnRNPA2/B1 
antibody (2μg per sample) for 2 hours at RT. RNA was collected from 800 μl of each sample 
using TRIzol and treated with DNase to remove contaminating DNA. MIR99AHG levels were 
analysed by TR-qPCR. The remaining 200 μl of each sample was collected, boiled for 10min 
and subjected to Western blot analysis. 
 
2.2.15 Western blot 
BMDMs were harvested and lysed in RIPA buffer supplemented with protease inhibitor (P-
8340, Sigma-Aldrich, US). Protein concentrations in cell lysates were measured using PierceTM 
BCA protein assay kit (23225, Thermo Fischer Scientific, US), and the same amount of protein 
was loaded and separated on a polyacrylamide gel. Proteins were transferred to a 
nitrocellulose membrane. Membranes were blocked with 5% BSA solution (prepared in TBST) 
for 2 hours and probed with primary antibodies overnight in dilution buffer (TBST 
supplements with 1% BSA). The antibodies used in western blots are: hnRNPA2/B1 (Santa 
cruz, sc-32316), hnRNPL (Abcam, ab6106), hnRNPK (Santa cruz, sc-28380), Cxadr (Santa cruz, 
sc-373791) and Gapdh (Santa Cruz, sc-365062). Membranes were probed with horseradish 
peroxidase-conjugated anti-mouse and anti-goat secondary antibodies (sc-2005 and sc-
2020). Western blots were developed with LumiGlo ReserveTM chemiluminescent substrate 
kit (54-64-01, Sera care, Life Sciences, MA, US).  
 
2.2.16 RNA sequencing and data analysis 
WT BMDMs were transfected with LNA GapmeRs and infected with Mtb HN878 MOI 1:2 for 
0, 4 and 24 hours. RNA seq libraries were prepared from total RNA and sequenced on Illumina 




2.2.17 In vivo GapmeR challenge 
Wildtype BALB/c mice were injected intraperitoneally with LNA GapmeR control (10mg/kg; 




Lungs sections were collected from euthanized mice and placed in 4% formaldehyde solution. 
Embedded sections were then stained with heamatoxin and eosin (H&E), or chromotrope 
aniline blue (CAB). The percentage of free alveolar spaces was defined as the open spaces in 
whole lung sections in relation to the total lung tissue area. Both free spaces and tissue areas 
were measured using the area measurement tool by the Nikon microscope imaging software 
NIS-elements and the % of alveolar spaces was calculated in Excel. A blinded quantification 
was performed to measure the percentage of MPO, CAB, CD3, iNOS, and Caspase-3 using the 
Nikon microscope imaging software NIS-elements. 
 
2.2.19 Flow cytometry  
Assessment of BMDM activation into M1 or M2 state was measured by flow cytometry. For 
surface staining, cells were labelled with appropriate antibodies (MHC11 (M5/114.15.2), 
CD11b (M1/70), CD64 (PM8), CD86 (558703), CD80 (553769) CD206 (C068C2), Pdl.2 (TY25) 
purchased from BD Bioscience (Franklin Lakes, NJ, US) and eBioscience (San Diego, CA, US). 
After incubation, cells were resuspended in FACS buffer for acquisition. Acquisition was 
performed using BD LSRFortessa (BD Bioscience, NJ, US) and data were analysed using FlowJo 
software (Treestar, Ashland, OR, US).  
 
2.2.20 Mtb infection and determination of burdens in mice 
Anaesthetized mice were infected intranasally with 25 μl of viable HN878 Mtb bacilli into each 
nasal cavity with doses of 100 CFU/mouse for immune response analysis. Bacterial loads, 
histopathological and flow cytometry analyses in lungs of Mtb-infected mice were 
determined as previously described [144]. The lung weight index calculation was performed 
as a measure of inflammatory infiltration using: square root [(Lung weight in mg/Mouse 
weight in g) *10]/10. Briefly, aseptically harvested lungs and spleen were homogenized in 
0.01% Tween-PBS and 10-fold dilutions were plated on 7H10 agar plates for the 
determinations of CFUs.   
 
 
2.2.21 Cell viability and apoptosis 
Assessment of apoptosis was analysed by flow cytometry using the FITC Annexin V Apoptosis 
Detection Kit II (BD Bioscience). After incubation, cells were resuspended in FACS buffer for 
acquisition. Acquisition was performed using BD LSRFortessa (BD Bioscience, NJ, US) and data 
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were analysed using FlowJo software (Treestar, Ashland, OR, US).  Cell viability was assessed 
usinf Cell Titer Blue (Promega, US). After incubation, data was analysed using VersamaTM 
Tumble microplate reader with Softmax Pro v6.3 (Avantor®, US). 
 
2.2.22 Statistical analysis 
All data were analysed using GraphPad Prism v6.0, a Student’s t-test (two-tailed with unequal 
variance) or unless otherwise stated in Figure legends. Means are shown as SEM., *P < 0.05, 






















Chapter 3: Mtb targets lincRNA-MIR99AHG for evasion in macrophages 
3.1 Introduction 
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is one of the leading 
infectious diseases in the world [1]. In 2018 it is estimated that TB caused more than 1.5 
million deaths and globally 10 million people developed TB[1]. Mtb is primarily transmitted 
by the respiratory route, and while it is able to cause disease in most organs, the most 
occurring is pulmonary tuberculosis [8].  As more awareness is gained into host factors 
involved in pathogen killing, new insights that target the host-pathogen interaction have 
become significant especially as  infectious pathogens affecting humans continue to infect 
and gain resistance from antimicrobials [3]. Mtb is able to utilize cellular host factors for its 
own survival and persistence [3]. By targeting and employing the host factors used by Mtb, 
this could lead to a reduction in pathology, mycobacterial burden and possible latency [3]. 
Immune cells are able to undergo changes in their transcriptional program in order to rapidly 
alter expression of genes which are important in host-defence [18]. The activation of the 
innate and adaptive immune cells is dependent on a coordinated set of transcriptional and 
post transcriptional events [18]. During these events many protein-coding genes are induced 
and repressed [18].  
 
Long noncoding RNAs (lncRNAs) are a family of noncoding RNAs (ncRNAs) [22, 23] mainly 
characterised as  >200 nucleotides [10]. lncRNAs are known to act via post transcriptional 
mechanisms targeting the splicing, stability, or translation of host mRNAs [38]. lncRNAs can 
act in cis- and trans- to regulate nearby genes or genes at other genomic locations [145]. Both 
cis- and trans-acting lncRNAS can activate or repress transcription through the recruitment of 
chromatin and modifiers [82, 146]. The function of lncRNAs in macrophage biology is recently 
emerging [12]. For example, lincRNA-EPS is an inhibitor of immune response gene (IRG) 
expression, acting as a regulatory checkpoint that is downregulated prior to inducible 
expression of IRGs [13]. Many other lncRNAs including lincRNA-Cox2 [14], THRIL [15], Mirt2 
[16], lnc13 [17] also regulate inflammatory genes in myeloid cells.  
 
Recent studies have reported on the role of lncRNAs during Mtb infection. In other immune 
cells such as T cells, CD244 signalling in TB correlated with high levels of lncRNA-CD244 in the 
CD244+CD8+ T-cell sub-population and lncRNA-CD244 acts as an epigenetic regulator of IFNγ 
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and TNF-α production in CD8+ T cells and impacts CD8+ T-cell immunity against active Mtb 
infection [64]. LncRNA-MEG3 was shown to eradicate mycobacteria  in macrophages infected 
with Mycobacterium bovis (BCG) via autophagy by targeting the mTOR and PI3K-AKT signalling 
pathways [68].  A microarray study revealed expression profiles of lncRNAs in human 
macrophages infected with Mtb virulent H37Rv and avirulent H37Ra strains and two lncRNAs, 
MIR3945HG V1 and MIR3945HG V2 were identified as novel candidate diagnostic markers for 
tuberculosis [71].  However, our understanding of the functional role of lncRNAs in polarized 
macrophages and during Mtb infection with a hypervirulent strain and their clinical relevance 
is still limited.  
 
In this study, we identify lincRNA-MIR99AHG which is abundantly expressed in IL-4/IL-13 
polarized mouse and human macrophages and downregulated in PBMCs from active TB 
patients. LincRNA-MIR99AHG was shown to regulate inflammatory gene expression in 
macrophages stimulated with IL-4/IL-13 and infected with Mtb. We investigated the function 
and regulatory mechanism of lincRNA-MIR99AHG. Knockdown of lincRNA-MIR99AHG in Mtb-
infected mice reduced the mycobacterial burden in lung and spleen. We found that lincRNA-
MIR99AHG regulates the expression of its nearby gene Coxsackie virus and adenovirus 
receptor (Cxadr) by interaction with hnRNPB2/A1. We show that lincRNA-MIR99AHG is 
downregulated in active TB patients and Mtb infected human monocyte-derived 
macrophages (MDMs) ex vivo. We propose a model whereby IL-4/IL-13-induced lincRNA-
MIR99AHG is a host-protective response following Mtb infection to inhibit Mtb intracellular 












3.2.1 MIR99AHG is induced by IL-4/IL-13 and repressed by Mtb HN878 infection 
We previously utilized deep CAGE (Cap Analysis of Gene Expression) transcriptomics to define 
the transcriptome of M1 (IFN-γ) or M2 (IL-4, IL-13, IL-4/IL-13) activated bone-marrow-derived 
macrophages (BMDMs) [142] and during Mtb infection [147]. Using this approach (Figure 
3.1A) we identified several differentially expressed lncRNAs with MIR99AHG being highly 
expressed in M2 (IL-4/IL-13) stimulated macrophages (Figure 3.1B). At 4 hours post 
stimulation, IL-4/IL-13 upregulated 150-fold the CAGE tags per million (TPM) expression of 
MIR99AGH when compared to the unstimulated macrophages. In contrast Mtb infection 
repressed MIR99AHG TPM expression in a time dependent manner (Figure 3.1C). The CAGE 
tags expression values of MIR99AHG was confirmed by RT-qPCR in cytokine stimulated and 
Mtb infected macrophages (Figure 3.1D-E). RT-qPCR also showed a slight induction of 
MIR99AHG by IFN-γ between 12 and 28 hours post stimulation (Figure 3.1D). This induction 
by IFN-γ was not as significant compared IL-4/IL-13 MIR99AHG induction in all three 
independent experiments performed. Altogether, these data show that MIR99AHG 
expression varies according to the macrophage polarization state, IL-4/IL-13 being the inducer 














































































































Figure 3.1 MIR99AHG is upregulated in M2 (IL-4/IL-13) activated macrophages and 
repressed in Mtb HN878-infected. (A-E) Bone marrow cells were differentiated for 10 days 
into BMDMs and stimulated with IFNγ or IL-4, IL-13, IL-4/IL-13. At 24 hours post-stimulation, 
BMDMs were infected with Mtb HN878 for 4, 24 and 48 hours. RNA was extracted from lysed 
cells at different time points post-stimulation and post-Mtb infection. (A) Timeline of mouse 
macrophage stimulation and Mtb HN878 infection.  
(B, C) CAGE analysis of MIR99AHG kinetic expression in non-infected and Mtb-infected 
BMDMs following stimulation. Two-way ANOVA and Bonferroni post-hoc test was used to 
evaluate statistical significance. Three independent experiments were performed.  
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(D, E) RT-qPCR analysis of MIR99AHG kinetic expression in stimulated and Mtb-infected 
BMDMs. The fold change in gene expression was determined by RT-qPCR and was normalised 
to HPRT expression. Each data point represents arithmetic mean of triplicates ± SD. Three 
independent experiments were performed. Student’s t-test was used to evaluate statistical 
significance, P values represented as, *P<0.05, ** P<0.01 and ***P<0.001. 
 
3.2.2 Knockdown of MIR99AHG reduces intracellular Mtb growth and inflammatory 
cytokines 
To examine the functional role of MIR99AHG in regulating intracellular growth of Mtb in 
macrophages, we performed lncRNA loss-of-function experiments using Locked Nucleic Acid 
(LNA) antisense oligonucleotides (ASOs) known as LNA GapmeRs. We first measured the 
knockdown efficiency in M2 (IL-4/IL-13) polarized macrophages and identified a 92% 
reduction of MIR99AHG expression at 4 hours post stimulation measured by RT-qPCR (Figure 
3.2A). We also examined the knockdown efficiency at 48 hours post transfection (70%) (Figure 
S1A) and at 4 hours post Mtb infection (69%) (Figure S1B). LNA GapmeR treatment for control 
and MIR99AHG did not result in any toxicity during cytokine stimulation and Mtb infection as 
we identified stable cell viability measured by the cell titre blue assay (Figure 3.2B and Figure 
S1D and E). 
 
To examine the functional role of MIR99AHG during Mtb infection, we inhibited MIR99AHG 
using LNA GapmeRs and analysed its effect on the intracellular growth of Mtb in macrophages 
by colony forming units (CFU) assays. Knockdown of MIR99AHG by LNA GapmeRs significantly 
reduced the intracellular Mtb growth in IL-4/IL-13 stimulated macrophages at 72 hours post 
Mtb infection (Figure 3.2C). Knockdown of MIR99AHG LNA GapmeRs led to an increased early 
apoptosis measured by AnnexinV+ and 7AAD- staining in IL-4/IL-13 stimulated BMDMs 
following Mtb infection, a possible mechanism of the reduced intracellular Mtb growth 
(Figure 3.2D). Nutlin is a known inducer of apoptosis. By RT-qPCR we confirmed apoptosis on 
BMDMs treated with nutlin and Mtb and there was an increased expression of Bax which is a 
pro-apoptotic marker and decreased Bcl2 expression an anti-apoptotic marker (Figure 3.2E 




To further characterize the functional role of MIR99AHG in cytokine production, we collected 
supernatant and RNA from LNA GapmeR transfected BMDMs and performed ELISA and RT-
qPCR. Protein and mRNA levels of IL-6 (Figure 3.2G) and IL-1β (Figure 3.2H) were significantly 
reduced in LNA GapmeR treated for MIR99AHG when compared to the control in IL-4/IL-13 
stimulated and Mtb-infected BMDMs. We measured nitrite production from BMDMs LAN 
GapmeR transfected, stimulated with IL-4/IL-13 and infected with Mtb. Knockdown of 
MIR99AHG by LNA GapmeRs reduced nitrite production compared to the control in IL-4/IL-13 
stimulated and Mtb infected BMDMs (Figure 3.2I). Silencing of MIR99AHG by LNA GapmeRs 
in BMDMs stimulated with IL-4/IL-13 and infected with Mtb led to a decrease in CD86, a 
known marker for classically activated macrophages (Figure 3.2J). These data suggest that 
Mtb targets MIR99AHG to promote intracellular Mtb growth in macrophages regulates 

























































































































































































































































Figure 3.2 Knockdown of MIR99AHG reduces intracellular Mtb growth in macrophages. 
BMDMs were antisense oligonucleotides (ASOs) transfected with locked nucleic acid (LNA)-
control and LNA-MIR99AHG, pre-stimulated with IL-4/IL-13 for 4 hours and infected with Mtb 
HN878. (A) Knockdown efficiency of LNA-GapmeRs analysed by RT-qPCR. Data representative 
of mean ± SD of triplicates. Three independent experiments were performed.  
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(B) Cell viability was measured in BMDMs at 4 and 72 hours post Mtb infection by Cell Titer 
Blue. Data representative of mean ± SD of triplicates. Three independent experiments were 
performed.  
(C) MIR99AHG downregulation reduces mycobacterial growth in macrophages. BMDMs were 
lysed at 4 hours for uptake and 72h post-Mtb infection to measure mycobacterial growth by 
CFU counting. Data representative of mean ± SD of triplicates. Three independent 
experiments were performed. 
(D) MIR99AHG downregulation favours apoptosis. BMDMs were stained with Annexin V+ and 
7-AAD- to identify live, early apoptotic, late apoptotic, necrotic cells and measured by flow 
cytometry. Data representative of mean ± SD of triplicates. Two independent experiments 
were performed. 
(E) Bax and Bcl2 mRNA expression by RT-qPCR in BMDMs treated with nutlin and infected with 
Mtb. Data representative of mean ± SD of triplicates. Three independent experiments were 
performed. 
(G, H) Protein and mRNA cytokine levels of IL-6 and IL-1β measured by ELISA and RT-qPCR. 
Data representative of mean ± SD of quadruplets. Three independent experiments were 
performed.  
(I, J) Nitrite production measured by Griess reagent and CD86 gMFI by flow cytometry 24 
hours post Mtb infection. Data represented as mean ± SD of triplicates. Three independent 
experiments. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001, Student’s t-test. 
 
 
3.2.3 Cis-acting MIR99AHG regulates the expression of nearby gene Cxadr 
Cxadr is a protein coding gene located downstream of MIR99AHG whereas Usp25 is located 
upstream. We examined the cis-acting regulatory effects of the MIR99AHG on these two 
proximal protein-coding genes. Using LNA GapmeRs, we silenced MIR99AHG and measured 
Cxadr and Usp25 expression by RT-qPCR in IL-4/IL-13 stimulated and Mtb infected BMDMs 
(Figure 3.3A-B). At mRNA level , knockdown of MIR99AHG in IL-4/IL-13 + Mtb infected BMDMs 
significantly downregulated Cxadr expression, suggesting a positive cis-regulatory effect. In 
contrast Usp25 was upregulated by the silencing of MIR99AHG suggesting a negative cis-
regulatory effect (Figure 3.3A-B). We employed Western blotting to further confirm the cis-
regulatory effect on the cognate genes Cxadr which is located downstream of MIR99AHG 
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(Figure 3.3C).  At 12 hours post infection, Mtb repressed Cxadr expression in a time dependent 
manner in IL-4/IL-13 stimulated macrophages (Figure 3.3D). In contrast, Mtb infection 
upregulated 350-fold the TPM expression of Usp25 in IL-4/IL-13 stimulated macrophages at 4 
hours post Mtb infection (Figure 3.3E).  
 
To assess the impact of MIR99AHG silencing on host immune response genes in macrophages, 
we performed RNA-seq in MIR99AHG knockdown BMDMs infected with Mtb for 4 and 24 
hours. The silencing of MIR99AHG altered the expression of 441 and 679 genes at 4 and 24 
hours post Mtb infection, respectively (P < 0.05) log2-fold change > 2. We identified 35 genes 
that were commonly upregulated and 26 genes that were commonly downregulated by 
MIR99AHG knockdown (Figure 3.3F). Most genes were genes were upregulated at 24 hours 
post Mtb infection. The upregulated genes were significantly enriched in terms related to 
regulation of inflammatory responses, response to bacteria, apoptotic cell death, and 

































































































Figure 3.3 Cis-acting MIR99AHG regulates expression of nearby gene, Cxadr. (A-C) BMDMs 
were antisense oligonucleotides (ASOs) transfected with locked nucleic acid (LNA)-control and 
LNA-MIR99AHG, pre-stimulated with IL-4/IL-13 for 4 hours and infected with Mtb HN878.  
(A, B) mRNA expression of mouse Cxadr and Usp25 analysed by RT-qPCR. Data representative 
of mean ± SD of triplicates. Three independent experiments were performed.  
38 
 
(C) Protein expression of mouse Cxadr and Usp25 analysed by western blot. Three 
independent experiments were performed.   
(D-E) CAGE analysis of Cxadr and Usp25 kinetic expression in BDMDs pre-stimulated with IL-
4/IL-13 and later Mtb infected. Data representative of mean ± SD of triplicates. Three 
independent experiments were performed. 
(F) Venn diagrams displaying the differentially expressed genes from LNA GapmeR transfected 
and Mtb infected BMDMs for 4 and 24 hours.  
(G) Heatmap of representative genes commonly upregulated and downregulated in 
MIR99AHG knockdown BMDMs between 4 and 24 of hours. Data are represented as mean ± 
SD of triplicates. Data shown is representative of three independent experiments. *P<0.05, 
and ****P<0.0001, Student’s t-test. 
 
3.2.4 In vivo treatment with LNA GapmeRs for MIR99AHG reduced mycobacterial burden 
in mice 
To compare the expression of MIR99AHG in vivo, we examined whole lung from Mtb infected 
mice or naïve lungs by RT-qPCR. MIR99AHG was downregulated in mice infected with Mtb at 
11 and 21 days post infection (Figure 3.4A). To confirm whether MIR99AHG suppression is 
virulence dependent, we infected BMDMs with different Mtb strains and examined the 
expression of MIR99AHG post Mtb infection (Figure S3A). Mycobacterium bovis (BCG) induced 
MIR99AHG expression while the virulent strains H37Rv and hypervirulent strain HN878 
inhibited MIR99AHG expression (Figure S2A). We also observed a similar suppression of 
MIR99AHG from whole lung infected with the Mtb clinical isolate CDC1551 and the virulent 
N0072 strain (Figure S2B). Targeting of noncoding RNAs to promote host innate defence is a 
promising strategy in the development of novel therapeutic interventions against TB [148, 
149]. To investigate whether the beneficial effects of MIR99AHG suppression could be 
translated into a host-directed therapy (HDT), we used Antisense LNA GapmeRs to inhibit 
MIR99AHG in a mouse Mtb infection model and tested its prophylactic efficacy. Mtb 
downregulates MIR99AHG, hence we employed a prophylactic treatment before Mtb 
infection to inhibit MIR99AHG. First, the mice were subcutaneously treated with LNA GapmeR 
for MIR99AHG or NC (negative control) at 10 mg/kg for alternate days up to day 14. Mice were 
then infected with the hypervirulent Mtb HN878 strain (100 CFU/mouse) intranasally for 21 
days. There was no difference in the Mtb uptake into lungs measured by colony forming units 
(CFU) assay at day 1 post infection between both treated groups, excluding possible role for 
different Mtb inoculation variable on the subsequent mycobacterial burden (Figure 3.4B). RT-
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qPCR results showed LNA-MIR99AHG GapmeR prophylaxis treatment drastically supressed 
MIR99AHG expression in lung tissues with a knockdown (KD) efficiency of 73% (Figure 3.4C). 
MIR99AHG KD mice showed significant reduced mycobacterial load in the lungs and in the 
spleen when compared to LNA GapmeR treated mice control mice (Figure 3.4D-E).   
 
At 3 weeks post infection there was no difference in lung weight index, and total lung cells 
between the control mice and MIR99AHG KD mice (Figure 3.4F-G). Lung inflammation was 
quantified by measuring alveolar spaces which were significantly increased in MIR99AHG KD 
mice compared to the control mice, indicative of reduced pulmonary lesions in MR99HAG KD 
mice (Figure 3.4H). Neutrophil influx into lungs was also reduced in MIR99AHG KD mice, 
quantified by tissue-damaging factor myeloperoxidase (MPO) staining (Figure 3.4I). T cell 
recruitment measured by CD3 staining was significantly reduced (Figure 3.4J). There was no 
significant different between the two groups in CAB (Chromotope Aniline Blue) staining 
indicating that that fibrotic tissues were similar between both groups (Figure 3.4K). Caspase-
3, a marker for apoptosis was increased in MIR99AHG KD mice compared to the control group 
(Figure 3.4L). iNOS, the enzyme responsible for producing the anti-mycobacterial effector 
molecule nitric oxide, was significantly reduced in MIR99AHG KD mice compared to the 
control group (Figure 3.4M, N). Also, at 3 weeks post infection MIR99AHG KD mice resulted in 
significantly reduced histopathology (H&E) in lungs compared to the control mice (Figure 
3.4N). Taken together, these results suggest in that MIR99AHG during Mtb infection 
contributes to increased histopathology due to increased pulmonary inflammation.  
 
To confirm if other infectious pathogens had a similar effect on the expression of MIR99AHG, 
whole spleen and lung of mice infected with Listeria monocytogenes showed downregulation 
of MIR99AHG (Figure S2C-D). This downregulation was also observed in BMDMs stimulated 
and infected with Leishmania mexicana (Figure S2E) suggesting that MIR99AHG is also 























































































































































































































Figure 3.4 Inhibition of MIR99AHG in vivo impedes intracellular survival of Mtb in mice. (A) 
RT-qPCR analysis of MIR99AHG expression on whole lung from wild-type (WT) mice infected 
with Mtb HN878 (100 CFU/mouse) for 11 and 21 days. BALB/c mice (n=6/mice/group) were 
antisense oligonucleotide (ASO) treated with 10 mg/kg locked nucleic acid (LNA)-control and 
LNA-MIR99AHG. (A) Knockdown efficiency (73%) of MIR99AHG at 14 days post ASO 
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treatment, analysed by RT-qPCR. (B) Mtb-infected mice were sacrificed at 24 hours post 
infection to determine the CFU lung uptake (n = 3 mice/per group). (C) Knockdown efficiency 
(73%) of MIR99AHG at 14 days post ASO treatment, analysed by RT-qPCR. (D-E) Mycobacterial 
burden of Mtb HN878-infected mice are shown with indicated CFU in lung and spleen at 3 
weeks post infection. (F) Lung weight index and (G) Total lung cell numbers. (H) Alveolar 
spaces at 3 weeks post infection were quantified from 4 deep cut H&E lung sections per mice 
(30 μm apart). (I-M) The percentage of positive MPO, CD3, CAB (Chromotrope Aniline Blue), 
Caspase-3 and iNOS staining per lung section was quantified from 1-2 deep cut lung sections 
per mice at 3 weeks post Mtb infection (30 μm apart). (N) Representative histopathology 
sections (x2 magnification) at 3 weeks post Mtb infection for H&E (scale bar=1000 μm). All 
error bars denote mean ± SD of triplicates. Data shown is representative of one experiment.  
*P < 0.05, **P<0.01, and ***P < 0.0001; Student’s t-test  
 
3.2.5 MIR99AHG leads to TB disease progression by inducing pro-inflammatory responses 
in the lung macrophages 
To better define cellular infiltration in the lungs, cell populations were analysed by flow 
cytometry, at 3 weeks post-infection with 100 CFU/mouse of Mtb HN878. There were no 
significant differences in number and percentages of alveolar macrophages, interstitial 
recruiting macrophages and monocyte-derived macrophages between the MIR99AHG KD 
mice and the control mice (Figure 3.5A, Figure S3A). Percentages of DCs were significantly 
higher and neutrophils significantly lower in MIR99AHG KD mice compared to the control 
(Figure 3.5B-C), however there was no significant differences in cell numbers (Figure S3B-C). 
T lymphocyte population in the lungs were not affected by the knockdown of MIR99AHG 
except for increased percentage of CD4+ Teffector cells (Figure 3.5D-E, Figure S3D-E).  
 
FACS sorting of neutrophils, alveolar macrophages, MoDCs and interstitial recruited 
macrophages population confirmed the silencing of MIR99AHG, with the control group still 
producing a significant amount of MIR99AHG (Figure 3.5F). Notably, alveolar and recruited 
interstitial macrophages from Mtb-infected MIR99AHG KD mice resulted in reduced levels of 
pro-inflammatory cytokines, such as il1b and il6 compared to control cells (Figure 3.5G-H). 
Anti-inflammatory cytokines il10 and tgfb were significantly reduced in alveolar and recruited 
interstitial macrophages and monocyte derived macrophages (Figure 3.5I-J). In addition, Nos2 
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was significantly reduced in alveolar and recruited interstitial macrophages from Mtb-infected 
MIR99AHG knockdown mice (Figure 3.5K). Similarly, M2 markers Arg1, Ym1 and Mrc1 were 
significantly downregulated in alveolar, recruited interstitial macrophages and monocyte 
derived macrophages (Figure 3.5L-N). These results indicate that MIR99AHG is involved in 
early inflammatory responses suggesting that alveolar, recruiting interstitial and monocyte 
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Figure 3.5 MIR99AHG leads to TB disease progression by inducing pro-inflammatory 
responses in lung macrophages. BALB/c mice (n=6/mice/group) were antisense 
oligonucleotide (ASO) treated with 10 mg/kg locked nucleic acid (LNA)-control and LNA-
MIR99AHG. Percentages of lung (A) CD11c+SiglecF+autofluorescemcehigh alveolar 
macrophages (AlvM), CD11b+CD64+LY6G- interstitial recruited macrophages (IntM) and 
CD11b+CD64+CD11c-monocyte-derived macrophages (moM); (B) CD11b−CD103+CD11c+ DC; 
(C) CD11b+Ly6G+ neutrophils; (D) CD3+CD4+, CD3+CD8+ T cells; (E) CD44lowCD62Lhigh naïve 
CD4+, effector CD44highCD62Llow CD4+ T cells and central memory CD44highCD62Lhigh CD4+. (F-
N) CD11b+CD64+Ly6G− interstitial recruited macrophages, CD11b+CD11c+MHCII+CD103− DC 
and CD11c+SiglecF+autofluorescencehigh alveolar macrophages were sorted by flow cytometry 
to determine mRNA expression of MIR99AHG, IL1b, IL6, IL10, TGFb, Nos2, Ym1, Arg1, and 
Mrc1. All data are represented as mean ± SD of triplicates. Data shown is representative of 
one experiment. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, Student’s t-test. 
 
3.2.6 MIR99AHG is repressed in macrophages exposed to TLR ligands and its expression is 
dependent on IL-4Rα signalling  
We employed RT-qPCR to examine the kinetics of MIR99AHG expression in BMDMs exposed 
to TLR ligands including LPS (TLR 4) and Pam3CSK4 (TLR2/1). The response of MIR99AHG was 
downregulated in BMDMs (Figure 3.6A) exposed to LPS and Pam3CSK4. Selective 
pharmacological inhibitors for NF-κB (Bay11-7084), Erk1/2 (FR180204, extracellular signal-
regulated kinase) and p38 (SB203580) were used to assess the functional consequences of 
inhibition of these pathways on MIR99AHG expression. Pre-treatment with Bay11-7084 and 
SB203580 upregulated MIR99AHG expression in LPS stimulated macrophages (Figure 3.6B-C). 
In addition, the selective Erk1/2 inhibitor FR180204 exerted inhibitory effects of MIR99AHG 
expression on Mtb infected BMDMs (Figure 3.6D). Induction of IL-6 and IL-1β was impaired in 
BMDMs pre-treated with FR180204 post Mtb infection (Figure 3.6E-F).  
 
Next, we sought to measure the expression MIR99AHG in MYD88-/- and IL-4Rα-/- mice. The 
TLR4 signalling is dependent on MYD88 and TRIFF [150], while IL-4 signals through two 
different receptor complexes, IL-4Rα or and IL-13Rα1 [151]. Since MIR99AHG is upregulated 
by IL-4/IL-13, we examined the expression of MIR99AHG in IL-4Rα-/- BMDMs and we observed 
a down regulation of MIR99AHG compared to the wild type in IL-4/IL-13 stimulated BMDMs 
(Figure 3.6G). In contrast, MIR99AHG expression was upregulated in IL-4Rα-/- BMDMs infected 
with Mtb compared to WT BMDMs (Figure 3.6H). MIR99AHG expression was downregulated 
in MYD88-/- BMDMs post LPS stimulation (Figure 3.6I). This suggests that MYD88 is not 
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involved in the control of MIR99AHG expression in LPS induced BMDMs. Collectively, these 
results indicate that MIR99AHG levels in macrophages are dynamically regulated in response 







































































































































































































Figure 3.6 MIR99AHG is repressed in macrophages exposed to TLR ligands. (A) RT-qPCR of 
MIR99AHG mRNA expression on BMDMs exposed to TLR-4 agonist (LPS, 100 ng/ml), TLR-2 
agonist (Pam3Csk4, 100 ng/ml).  (B-D) RT-qPCR of MIR99AHG mRNA expression on BMDMs 
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were pre-treated for 1 hour with selective pharmacological inhibitors for NF-ᴋB (Bay11-7084, 
10 μM), p38 (SB203580, 5 μM) and Erk1/2 (FR180204, 10 μM), then activated by LPS 
stimulation (100 ng/ml)  for 24h or infected with Mtb HN878 (MOI 1:2) for 24h. Data 
representative of mean ± SD of triplicates. Three independent experiments were performed. 
(E, F) IL-6 and IL-1β protein production measured by ELISA. Data representative of mean ± SD 
of triplicates. Three independent experiments were performed. 
(G-I) MIR99AHG expression from IL-4Rα-/- and MYD88-/- BMDMs stimulated with IL-4/IL-13, 
LPS and Mtb. Error bars denote mean ± SD of triplicates. Three independent experiments were 
performed.  *P<0.05, **P<0.01 and ***P<0.001, Student’s t-test. 
 
3.2.7 MIR99AHG is translocated from the cytoplasm to the nucleus following IL-4/IL-13 
stimulation in macrophages and functions by interacting with hnRNPA2/B1 
To understand how MIR99AHG regulates inflammatory responses in macrophages, we 
examined its location by performing sub-cellular fractionation and analysed the expression of 
MIR99AHG by RT-qPCR. This analysis revealed that MIR99AHG was predominantly found in 
the cytoplasm in unstimulated BMDMs but with IL-4/IL-13 stimulation we observed a 
significant expression of MIR99AHG in the nucleus (Figure 3.7A) suggesting that MIR99AHG 
may exert its biological functions in the nucleus.  
 
To identify MIR99AHG binding proteins, we performed RNA pulldown assay by incubating in 
vitro transcribed biontylated MIR99AHG and its antisense control RNA with nuclear extracts 
from IL-4/IL-13 stimulated and Mtb infected BMDMs. The associated proteins were pulled 
down and analysed by mass spectrometry. We identified the 6 most enriched MIR99AHG-
binding proteins based on the number of peptides specifically associated with MIR99AHG 
(Figure 3.7B). Among the 6 genes examined, hnRNPA2/B1 had the highest number of peptides 
associated with MIR99AHG (Figure 3.7B). To confirm hnRNPA2/B1-MIR99AHG interaction we 
performed RNA immunoprecipitation (RIP) of endogenous hnRNPA2/B1 nuclear extracts of 
IL-4/IL-13 stimulated and Mtb infected BMDMs followed by RT-qPCR and western blot (Figure 
3.7C-D). Though we show MIR99AHG-hnRNPA2/B1 interaction, more studies that investigate 
the functional consequences of the inhibition of hnRNPA2/B1 on MIR99AHG and its target 
genes still need to be explored to fully substantiate this interaction. Altogether, these data 























C y to p la s m
- IL -4 / IL -1 3 - IL -4 / IL -1 3
***
****


































































































































Figure 3.7 MIR99AHG is localized in the nucleus in IL-4/IL-13 stimulated macrophages and 
functions by interacting with hnRNPA2/B1. (A) RT-qPCR analysis of RNAs purified from 
nuclear and cytoplasm compartments in BMDMs stimulated with IL-4/IL-13 for 4h. Data 
representative of mean ± SD of triplicates. Three independent experiments were performed. 
(B) Candidate MIR99AHG-binding proteins identified by mass spectrometry. Data shown 
Srepresentative of one experiment.  
(C) RT-qPCR analysis of MIR99AHG in anti-hnRNPA2/B1 antibody or control IgG 
immunoprecipitates from nuclear lysates of LNA-Control or LNA-MIR99AHG knockdown 
macrophages stimulated with IL-4/IL-13 and infected with Mtb. Error bars denote mean ± SD 
of triplicates. Data shown are representative of one experiment.   
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(D) Western blot analysis of hnRNPA2/B1 in Input, anti-hnRNPA2/B1 antibody and control IgG 
immunoprecipitates from nuclear lysates of LNA-Control or LNA-MIR99AHG knockdown 
macrophages stimulated with IL-4/IL-13 and infected with Mtb. Data shown are 
representative of one experiment. 
(E, F) Western blot analysis of hnRNPA2/B1 in Input and anti-hnRNPA2/B1 antibody 
immunoprecipitates from nuclear lysates of LNA-MIR99AHG knockdown macrophages 
stimulated with IL-4/IL-13 and infected with Mtb. Data shown are representative of two 
experiments. ***P < 0.001 and ****P < 0.0001, Student’s t-test. 
 
3.2.8 Suppression of MIR99AHG in Mtb-infected human macrophages and active TB 
patients 
To confirm the mouse macrophages results in human macrophages, we have examined the 
expression of MIR99AHG in human monocyte-derived macrophages (MDMs). Similar to 
BMDMs, MIR99AHG was upregulated by IL-4/IL-13 stimulation and downregulated by Mtb 
HN878 infection (Figure 3.8A-B). We employed RT-qPCR to examine the kinetics of MIR99AHG 
expression on LNA GapmeR transfected human MDMs exposed to IL-4/IL-13 and Mtb 
infection. The expression of MIR99AHG was downregulated after stimulation and Mtb 
infection (Figure S4A-B). Cell viability was confirmed on human MDMs by CellTitre-blue 
(Figure S4D-F). Knockdown of MIR99AHG with LNA GapmeRs reduced Mtb intracellular 
growth in MDMs (Figure 3.8C). mRNA levels of Bax were increased in nutlin treated and Mtb 
infected macrophages treated with LNA GapmeR for MIR99AHG (Figure S4G-H). Knockdown 
of MIR99AHG with LNA GapmeRs in MDMs stimulated with IL-4/IL-13 followed by Mtb 
infection reduced IL-6 protein levels (Figure 3.8D). 
 
Next, we examined MIR99AHG expression in MDMs from healthy donors infected with Mtb 
HN878. There was a suppression of MIR99AHG post Mtb infection in a time dependent 
manner (Figure 3.8E). Human CXADR was also downregulated in a time dependent manner 
post Mtb infection (Figure 3.8F). Finally, we re-stimulated PBMCs from active and healthy TB 
patients with IL-4/IL-13 and heat killed (HK) Mtb. MIR99AHG expression is reduced in active 
TB patients compared to healthy patients (Figure 3.8G). Taken together these results 































































































































































































































Figure 3.8 Suppression of MIR99AHG in Mtb-infected human macrophages and active TB 
patients. (A) RT-qPCR analysis of MIR99AHG kinetic expression in stimulated and (B) Mtb-
infected MDMs. Data representative of mean ± SD of triplicates. Data representative of one 
experiment. 
(C) MDMs were LNA GapmeR transfected with control and MIR99AHG, pre-stimulated with 
IL-4/IL-13 for 4 hours and infected with Mtb HN878. Cells were lysed at 4h for uptake and 24 
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and 48h post-Mtb infection to measure bacterial growth by CFU counting. Data representative 
of mean ± SD of triplicates. Three independent experiments were performed. 
(D) IL-6 production on MDMs pre-stimulated with IL-4/IL-13 and infected with Mtb HN878 
measured by ELISA. Data representative of mean ± SD of triplicates. Three independent 
experiments were performed. 
(E) RT-qPCR analysis of human MIR99AHG expression on MDMs from healthy donors infected 
with Mtb HN878. Data representative of mean ± SD of triplicates. Three independent 
experiments were performed. 
(F) RT-qPCR analysis of human CXADR expression on MDMs from healthy donors infected with 
Mtb (HN878) ex vivo. Data representative of mean ± SD of triplicates. Three independent 
experiments were performed. 
(G) Re-stimulated PBMCs from healthy and active TB patients analysed by RT-qPCR. Error bars 
denote mean ± SD of triplicates. Data shown are representative of one experiment. P values 
represented as, *P<0.05, Student’s t-test. 
 
3.3 Discussion 
Mtb is an intracellular pathogen that can evade lysosomal degradation and establish 
persistent infections. Host-directed drug therapies (HDTs) main purpose is to eliminate Mtb 
with minimal damage to the host [152]. HDTs include different groups of compounds, such as 
cytokines, repurposed-drugs that target biologically and clinically relevant checkpoints in anti-
Mtb-directed host response pathways [152]. 
 
Macrophages are derived from monocyte precursors and undergo specific differentiation 
depending on the local tissue environment. M1 (IFNγ/LPS) macrophages are characterized by 
production of pro-inflammatory mediators such as nitric oxide (NO) usually associated with 
the control of infection [153]. In contrast, M2 (IL-4/IL-13) macrophages are immune 
modulators by secreting more ornithine and support a Th2-associated effector function [153].  
Mtb has evolved different strategies to interfere with M1 (IFNγ/LPS) polarization, neutralize 
microbicidal effectors to promote M2 (IL-4/IL-13) polarization resulting in its persistence and 
survival in the macrophages [153]. Effective immune defence against invading pathogens is 
dependent on a wide transcriptional program in macrophages and other immune cells [18]. 
Factors such as chromatin remodelling, transcription factor activation, receptor ligation and 
signalling all coordinate the duration and intensity of these responses [18]. While the role of 
miRNAs in the regulation of inflammatory responses has been well studied [154], the role of 
50 
 
long noncoding RNAs in polarized macrophages and during infection with infectious 
pathogens is still poorly understood.  
 
In this study, we demonstrate that MIR99AHG is highly upregulated by IL-4/IL-13 stimulation 
and downregulated by Mtb infection in macrophages. Using loss-of-function approach, we 
gained insights into the biological functions of MIR99AHG at both cellular level and organismal 
level. Knockdown of MIR99AHG reduced intracellular Mtb growth in mouse and human 
macrophages and induced apoptosis. Knockdown of MIR99AHG reduced pro-inflammatory 
cytokines such as IL-6 and IL-1β. Knockdown of MIR99AHG impaired the expression of the 
neighbouring gene coxsackie virus and adenovirus receptor (Cxadr) suggesting a cis-
regulatory role. Our mechanistic studies also show that MIR99AHG functions through is 
interaction with hnRNPA2/B1. The evidence from the fractional RNA extraction reveals that 
MIR99AHG is translocated to the nucleus post IL-4/IL-13 stimulation. 
 
MIR99AHG was previously identified and referred to as MONC [29]. MIR99AHG was reported 
to be spliced into a 710-nucleotide lincRNA, where intron 6 of MONC produces the miRNAs 
MIR99A, LET7C and MIR125B2 [29].  Emmrich et al. [29] found that knockdown of MIR99AHG 
in AMKL cell lines with high endogenous MIR99AHG expression reduced cell growth and 
colony-forming capacity [29]. Knockdown of MIR99AHG induced apoptosis and changed 
megakaryocytic-erythroid surface markers in a cell-line dependent manner [29]. Our findings 
show similarity to what was reported [29], suggesting that MIR99AHG may function in a 
similar manner to other disease models. This is further supported by the observed 
downregulation of MIR99AHG by other intracellular pathogens (Figure S2C-E).  
  
Knockdown of MIR99AHG reduced Mtb intracellular growth and induced apoptosis in both 
mouse and human macrophages (Figure 2C-D and Figure 8C). The way macrophages respond 
following Mtb infection is very crucial to the host immune response and the outcome of the 
infection. Apoptosis is one of the major outcomes observed following established Mtb 
infection in macrophages and an important host defence mechanism [155]. It has been 
reported that apoptosis is able to control bacterial growth, however virulent strains of Mtb 
have been reported to inhibit the completion of apoptosis [156]. This is a virulence 
mechanism used by the pathogen to escape host defences, and results in necrosis and 
51 
 
persistent infection of the surrounding macrophages [156].  Our results suggest that 
apoptosis is used as a host defence mechanism to control Mtb infection. The secretion of pro-
inflammatory cytokines is very important in the protection against Mtb infection. To maintain 
control of Mtb infection cytokines such as IFNγ, TNFα, IL-6, IL-1β are needed [157]. We sought 
to examine whether knocking down MIR99AHG would have any altered effect on the above-
mentioned cytokine production given their role in the control of Mtb infection.  Knockdown 
of MIR99AHG reduced the production of IL-6 and IL-1β in M2 (IL-4/IL-13) and Mtb infected 
macrophages suggesting that MIR99AHG may be a positive regulator of inflammation. Quite 
a few long noncoding RNAs have been reported to be important regulators of inflammation 
or act as “brakes” in controlling excessive inflammation [13, 14, 16, 158]. Our results suggest 
that MIR99AHG may play a crucial role as a potential regulator of macrophage polarization 
and inflammation while Mtb manipulates the host response by downregulating MIR99AHG to 
enable its survival in macrophages. 
 
An important finding in our study is that MIR99AHG has a cis effect on its neighbouring gene 
Cxadr. Cxadr is an important cellular protein that is involved in cell-adhesion, protein 
trafficking and viral infection [159]. Most lncRNAs have been reported as trans-acting 
regulators of protein-coding genes, such as lincRNA-COX2 [14] and NEAT1 [160]. While the 
importance of trans-acting lncRNAs in regulating immune response is highlighted in these 
studies, there remains a gap in the role of cis-regulatory lncRNAs in immune responses. A 
recent study published by Zhang and colleagues [158] identified a cis-acting lncRNA named 
ROCKI which regulates inflammatory gene expression. Regulation of gene expression by cis-
acting lncRNAs may involve regulatory components in gene promoters, the process of 
transcription or splicing, or the sequence /structure of the RNAs [161]. However, many studies 
have shown that cis-regulatory functions of lncRNAs were dependent on sequence/structure 
of RNAs [162, 163]. Our study identifies MIR99AHG as a cis-regulatory lncRNA and further 
adds support to the role of cis-acting lncRNAs in immune regulation. 
 
There are increasing studies of lncRNAs that have been functionally characterized especially 
in cancer models, however there is limited data on characterized lncRNAs in a TB disease 
model. Mouse models that use genetic deletion or antibody inhibition have shown an 
association between components of the immune system and survival upon Mtb challenge 
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[164]. Studies that have been performed on mouse models have also corresponded with 
observation made in humans hence data from mouse models is very crucial on improving 
current therapeutic interventions [164]. TB animal models are crucial for developing 
biomarkers of diagnosis, drug therapy, vaccines and for researching mechanisms that identify 
targets [165]. Recent studies have shown strong evidence on the role of lncRNAs in the 
modulation of innate and adaptive immune response. Findings from animal models, using 
systemic administration of antisense oligonucleotides (ASO), serve as a translational proof of 
concept for therapeutic interventions targeting lncRNAs [166]. In this study, we provide 
evidence for the regulation of immunity to Mtb by MIR99AHG. We explored the role of 
MIR99AHG in a loss of function approach. We used Mtb-infected mice systemically 
administered with LNA GapmeRs in comparison to infected negative control (NC) mice. 
Interestingly, MIR99AHG KD mice were highly resistant to TB disease exhibiting reduced tissue 
inflammation and pulmonary histopathology. We also show there is increased Caspase-3, a 
marker for apoptosis, in MIR99AHG KD group compared to the control. These results are 
consistent with our in vitro data. Unfortunately, we could not detect Arg1 on both groups at 3 
weeks post infection. A study which showed that IL-4Rα does not play a significant role in TB 
disease progression also showed that Arg1 was not yet produced in the lungs of mice at four 
weeks post Mtb infection suggesting that Arg1 is induced at a later stage of infection [144]. 
Many studies have shown that miRNAs are involved in host responses to Mtb [167, 168], 
however there is limited research on the functional role of lncRNAs involved in host responses 
to Mtb infection.  We show for the first time that treatment with MIR99AHG ASOs significantly 
reduced the pathogenesis of Mtb infection, suggesting that MIRR9AHG could be repurposed 
for host-directed therapy for TB.  
 
Our mechanistic studies indicate that MIR99AHG functions by interacting with hnRNPA2/B1. 
Interestingly, this protein has been identified to interact with lincRNA-COX2 [14]. hnRNPs are 
important functional partners for many additional lncRNAs. These include lincRNA-EPS which 
interacts with hnRNPL [13], lincRNA-p21 which interacts with hnRNPK [169] and Xist which 
interacts with hnRNPU [170]. hnRNPs are well known to be involved in mRNA biogenesis. In 
addition, the role of hnRNPA2/B1 in transcriptional regulation of gene expression is also 
beginning to emerge. For example, hnRNPA2/B1 was shown to interact with small activating 
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dsRNA to induce transcriptional activation [171]. Moreover, hnRNPA2/B1 regulates smooth 
muscle cell (SMC) differentiation gene expression transcriptionally and promotes neural crest 
cell migration and differentiation toward SMC [172]. Although in this study we show that 
MIR99AHG interacts with hnRNPA2/B1, more studies to substantiate this claim are needed. 
The identification of hnRNPA2/B1 as a functional binding partner of MIR99AHG adds further 
support to the role of hnRNPs in transcriptional regulation and expanding the role of these 
binding proteins beyond their well-known functions in mRNA processing. 
 
RT-qPCR on fractionated RNA showed a nuclear localization of MIR99AHG. In the nucleus, it 
is most likely that RNAs play an important role in the organization of nuclear domains [173]. 
LncRNAs control the epigenetic state of particular genes, participate in transcriptional 
regulation, involved in alternative splicing and constitute subnuclear compartments [173]. In 
the nucleus, lncRNAs can act in cis or trans, for example Morrbid interacts with PRC2 to 
repress transcription of the neighbouring gene, Bim (Bcl2l11), in cis in short-lived myeloid cells 
such a s neutrophils and monocytes [174]. A lncRNA can interact with its protein partner as a 
guide (lincRNA:hnRNPL) [13], scaffold (RMRP interaction with DDX5 and RORγt) [175] or 
decoy molecule (Lethe:NF-κB p65) [176] to mediate its molecular functions. Cellular 
localization of lncRNAs can help with studies involving functions and mechanisms of action. 
Further studies in identifying the exact sub-nuclear areas and DNA target sequences of 
MIR99AHG are needed.  
  
3.4 Conclusion 
In conclusion, this study functionally validates for the first time the role of MIR99AHG during 
Mtb infection. MIR99AHG plays a role in the regulation of inflammatory genes, neighbouring 
gene and Mtb persistence in macrophages. In active TB patients, and Mtb-infected mice and 
human macrophages. MIR99AHG contributes to the maintenance of Mtb growth. Identifying 
the role of MIR99AHG during Mtb infection will ultimately provide a novel treatment 

























































































































Figure S1. Knockdown efficiency and cell viability following LNA GapmeR treatment. (A, B) 
Knockdown efficiency of MIR99AHG on LNA GapmeR transfected BMDMs at 48 hours post 
transfection and 4 hours post Mtb infection, analysed by RT-qPCR. (C, D) Cell viability of LNA 
GapmeR transfected BMDMs at 24-72 hours post Mtb infection. Error bars denote mean ± SD. 
Data shown are representative of three independent experiments. *P<0.05, **P<0.01, 
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Figure S2. MIR99AHG is suppressed by other intracellular pathogens. (A) BMDMs were pre-
stimulated with IL-4/IL-13 for 4 hours then infected with different Mtb strains for 24 hours to 
measure MIR99AHG mRNA by RT-qPCR. Error bars denote mean ± SD of triplicates. Two-way 
ANOVA and Bonferroni post-hoc test was used to analyse the statistical significance. Data 
shown are representative of one experiment.  
(B) MIR99AHG mRNA expression measured by RT-qPCR in whole lung from wild-type mice 
infected with different Mtb strains (100 CFU/mouse) for 11 days. Error bars denote mean ± 
SD of triplicates. Two-way ANOVA and Bonferroni post-hoc test was used to analyse the 
statistical significance. Data shown are representative of one experiment. 
(C, D) MIR99AHG mRNA expression measured by RT-qPCR in whole lung and spleen from wild-
type mice infected with Listeria monocytogenes (2x105 CFU/mouse) at 2 dpi. Error bars denote 
mean ± SD of triplicates. Data shown are representative of one experiment. 
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(E) Expression of MIR99AHG mRNA measured by RT-qPCR from BMDMs pre-stimulated with 
IFN-γ or IL-4/IL-13 for 4 hours and infected with Leishmania mexicana. Error bars denote mean 
± SD of triplicates. Data shown are representative of three independent experiments.  
(F) Western blot analysis of hnRNPA2/B1 in Input and anti-hnRNPA2/B1 antibody 
immunoprecipitates from LNA-MIR99AHG knockdown macrophages stimulated with IL-4/IL-
13 and infected with Mtb. Bands were cut from previous experiments. P values represented 










T o ta l D C s
0
5 .01 0 5
1 .01 0 6









N e u t
0
2 .01 0 6
4 .01 0 6
6 .01 0 6









C D 4 C D 8
0
1 .01 0 6
2 .01 0 6
3 .01 0 6










n a ïv e T Ef f T CM
0
2 .01 0 6
4 .01 0 6





















Figure S3. Lung myeloid and lymphoid cell numbers in cell populations following Mtb HN878 
infection in MIR99AHG knockdown mice. Mice were LNA GapmeR treated with negative 
control and MIR99AHG at 10 mg/kg for alternative days up to day 14. Mice were infected 
intranasally with 100 CFU/mouse of Mtb HN878 (n=6 mice/group) and sacrificed at 3 weeks 
post-infection. (A) Cell numbers of lung CD11c+SiglecF+autofluorescencehigh alveolar 
macrophages (AlvM), lung CD11b+ F4/80+Ly6G- interstitial recruited macrophages (IntM) and 
CD11b+CD64+CD11c-monocyte-derived macrophages (moM); (B) lung 
CD11b+CD11c+MHCII+CD103- Ly6C- and lung CD11b-CD103+CD11c+ DC; (C) lung CD11b+Ly6G+ 
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neutrophils. (D, E) Cell numbers of lung lymphoid CD3+CD4+, CD3+CD8+ T cells, 
CD44lowCD62Lhigh naïve CD4+, effector CD44highCD62Llow CD4+ T cells and central memory 
















































































































































































































































Figure S4. Knockdown efficiency MIR99AHG following LNA GapmeR treatment in human 
MDMs. (A-C) Human MIR99AHG and CXADR knockdown efficiency on human MDMs pre-
stimulated by IL-4/IL-13 for 4 hours and infected with Mtb HN878, analysed by RT-qPCR. Error 
bars denote mean ± SD. Data shown are representative of three independent experiments. 
(D-F). Cell viability of LNA GapmeR transfected human MDMs pre-stimulated with IL-4/IL-13 
for 4 hours and infected with Mtb for 4 to 48 hours. Error bars denote mean ± SD. Data shown 
are representative of one experiment. 
(G, H). Bax and Bcl2 mRNA expression measured by RT-qPCR from LNA GapmeR transfected 
human MDMs treated with nutlin, rapamycin and Mtb infection for 24 hours.  Error bars 
denote mean ± SD of triplicates. Data shown are representative of one experiment.  P values 





















Chapter 4: IL7-AS promotes Mtb intracellular growth through regulation of inflammatory 
genes 
4.1 Introduction 
Mycobacterium tuberculosis (Mtb) remains the leading bacterial cause of death in humans 
worldwide (1.5 million deaths per year) [1]. Mtb is predominantly transmitted by the 
respiratory route, and while it is able to cause disease in most organs in the body, the most 
reported and occurring is pulmonary tuberculosis where it establishes its niche within 
macrophages [8]. The innate system is the first defence against invading pathogens through 
activating inflammatory responses [177]. Macrophages, dendritic cells and neutrophils are 
known to play important roles as antigen presenting cells (APCs) in the innate host defence 
[8].  
Long non-coding RNAs were initially identified in mice through FANTOM project [178]. Long 
non-coding RNAs (lncRNAs) are mainly classified as either short noncoding RNA (< 200 
nucleotides) or long noncoding RNA (> 200 nucleotides) [10]. LncRNAs are classified according 
to their position to protein coding genes which include antisense (AS), long intergenic 
(lincRNA) and pseudogenes [10]. Many of these lncRNAs are commonly induced post 
activation of the innate immune response [179]. LncRNAs have emerged as key regulators of 
chromatin remodelling, transcription and posttranscriptional gene regulation in the innate 
immune system [180].  
Recent publications have identified several lncRNAs that are differentially expressed following 
activation of the innate immune response which leads to subsequent regulation of 
inflammatory response. Many studies in mice have identified lincRNA-Cox2 [14, 58], lincRNA-
EPS [13], Mirt2 [16] and IL7-AS [30], while in humans these include THRIL [15], IL7-AS [31], 
lnc-IL7R [43] and IL1β-RBT [181]. LncRNA IL7-AS is newly discovered and has been reported 
to be located antisense to IL-7 and induced in many mice and human cell types following 
exposure to LPS or IL-1β [31]. Knockdown of IL7-AS was shown to not have a significant effect 
on the mRNA expression of IL-7 in A549, THP-1 and RAW264.7 cell lines [31].  Another 
publication has shown that IL7-AS is differentially expressed in human lung fibroblasts 
following IL-1β induction to negatively regulate IL-6 [179]. Recently, this lncRNA has been 
shown to be dependent on the NF-κB and MAPK signalling pathways in macrophages and 
epithelial cells and also induce the expression of CCL2, CCL5 and CCL7 [182]. 
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There are few publications that have shown the functional role of lncRNAs during Mtb 
infection [64, 68]. However, despite the role of these lncRNAs during Mtb infection and 
following the activation of the innate immune response, there has been no attempt to identify 
the role of lncRNAs in polarised macrophages and/or during Mtb infection. To address this 
issue, we determined the functional role of lncRNA IL7-AS in mouse and human polarized 
macrophages and during Mtb infection. In this study we show that IL7-AS is highly induced 
following Mtb infection. IL7-AS appears to negatively regulate IL-6, IL-1α, IL-1β and IL-12 in 
Mtb infected macrophages. Knockdown of IL7-AS does not seem to have a significant impact 
on the mRNA production of IL-7 suggesting that the function if IL7-AS is not dependent on IL-
7 in cis. We also show that it is dependent on the NF-κB and MAPK signalling pathways in 
macrophages. We show the relevance of IL7-AS in active TB patients and in human 
macrophages. Therefore, our data show an important role of IL7-AS as a promoter of Mtb 
growth and transcriptional activator of inflammatory genes during Mtb infection.  
4.2 Results 
4.2.1 IL7-AS is induced following Mtb infection 
Using the same approach to identify lincRNA-MIR99AHG, we utilized CAGE transcriptomics to 
identify IL-7AS from activated BMDMs [142] and during Mtb infection [147]. From this 
approach we identified several differentially expressed lncRNAs that were either upregulated 
or downregulated in polarized and/or Mtb infected BMDMs. We chose IL7-AS because it was 
highly upregulated by Mtb, an opposite effect to what we observed with lincRNA-MIR99AHG. 
BMDMs were either stimulated towards an M1 (IFN-γ) or M2 (IL-4, IL-13, IL-4/IL-13) 
phenotype and/or infected with Mtb HN878 hypervirulent strain (Figure 4.1A). IL7-AS was 
one of the two lncRNAs that is upregulated by Mtb infection from our top 9 validated list of 
lncRNAs. There was no clear indication of which macrophage polarization phenotype had the 
most effect on IL7-AS, however upon Mtb infection we could observe a drastic upregulation 
of IL7-AS. (Figure 4.1B-C). Mtb infection upregulated 150 fold the TPM expression of IL7-AS 
compared to the unstimulated macrophages (Figure 4.1C). The expression of IL7-AS post 




4.2.2 Knockdown of IL7-AS reduces intracellular Mtb growth through apoptosis and 
regulation of the transcription of inflammatory genes  
To understand and validate the role of IL7-AS during Mtb infection we performed functional 
experiments on BMDMs and human MDMs using Locked Nucleic Acid (LNA) chemically 
engineered antisense oligonucleotides (ASOs) known as LNA GapmeRs. To examine the 
functional role of IL7-AS on intracellular growth of Mtb in macrophages, we inhibited IL7-AS 
using LNA antisense oligonucleotides (ASOs). The knockdown efficiency was at 60% and 53% 
at 24 and 48 hours post transfection, respectively (Figure 4.2A). 
 
Cell viability was confirmed using Cell-Titre blue assay (Figure 4.2C). Next, we examined the 
functional role IL7-AS during Mtb infection by analysing its effect on the intracellular survival 
of Mtb by CFU assays. Knockdown of IL7-AS drastically reduced intracellular bacterial growth 
in unstimulated BMDMs (Figure 4.2B). By RT-qPCR we confirmed that knockdown of IL7-AS 
increased apoptosis in BMDMs treated with nutlin, an apoptosis inducer, and post Mtb 
infection by measuring mRNA levels of Bax and Bcl-2 (Figure 4.2D).  To further characterize 
IL7-AS, we performed ELISA from BMDMs infected with Mtb. Knockdown of IL7-AS increased 
protein levels of IL-1α, IL-1β, IL-6 and IL-12 compared to the control (Figure 4.2E-I). We 
performed a Griess reagent assay and arginase assay to measure nitrite and arginase 
production post Mtb infection. Knockdown of IL7-AS increased nitrite production while there 
was no effect on arginase production (Figure 4.2J-K). These results suggest apoptosis 
enhancement and heightened pro-inflammatory gene response might account for the 
mechanisms behind the reduced intracellular Mtb growth. These data also suggest that Mtb 
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Figure 4.1 IL7-AS is highly induced by Mtb infection. (A) Timeline of mouse macrophage 
activation and Mtb HN878 infection. Bone marrow cells were differentiated for 10 days into 
BMDMs and stimulated with IFNγ or IL-4, IL-13, IL-4/IL-13. At 24 hours post-stimulation, 
BMDMs were infected with Mtb (HN878) for 4, 24 and 48 hours. RNA was extracted from 
lysed cells at different time points post-stimulation and post-Mtb infection. (B, C) CAGE 
analysis of IL7-AS kinetic expression in non-infected and Mtb-infected BMDMs. The fold 
change in gene expression was determined by RT-qPCR and was normalised to HPRT 
expression. Three independent experiments were performed. 
(D, E) RT-qPCR analysis of IL7-AS kinetic expression in stimulated and Mtb-infected BMDMs. 
Data is representative of three independent experiments. Each data point represents 





4.2.3 IL7-AS functions independently of IL-7 
The mouse and human homologs of IL7-AS were renamed as a result of their antisense 
overlap with the promoter region of IL-7, a cytokine which is known to play an important role 
in B and T cell development [183]. To confirm whether knockdown of IL7-AS has any 
regulatory effects on the expression of IL-7, we performed RT-qPCR on BMDMs. Knockdown 
of IL7-AS increased the expression of IL-7 in a time dependent manner in unstimulated and 
Mtb infected BMDMs (Figure 4.3A-C). To determine whether loss of function of IL7-AS on 
BMDMS stimulated with IL-7 had any significant role in mycobacterial growth, we performed 
a CFU assay. Our results show that IL-7 stimulation does not have any significant impact on 
reducing Mtb intracellular growth in early time points except at 72 hours post Mtb infection 
(Figure 4.3D).  We collected supernatant from unstimulated and IL-7 stimulated BMDMs and 
measured protein levels of IL-7 using the ELISA. Knockdown of IL7-AS in unstimulated and 
stimulated BMDMs increased protein levels of IL-7 in a negative regulatory manner (Figure 
4.3E-F). Silencing of IL7-AS on BMDMs stimulated with IL-7 and Mtb infected did not have an 
impact on nitrite production however, arginase production was reduced (Figure 4.3G-H). 
These data suggest that despite the negative regulation of IL7-AS on IL-7, the intracellular Mtb 
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Figure 4.2 IL7-AS promotes Mtb growth by regulating the transcription of inflammatory 
genes.  
(A) Knockdown efficiency of LNA-IL7-AS post LNA GapmeR transfection on BMDMs. Each data 
point represents arithmetic mean of triplicates ± SD. Three independent experiments were 
performed. 
(B) BMDMs were LNA GapmeR transfected with LNA control and LNA IL7-AS and infected with 
Mtb. Cells were lysed at 4 hours for uptake and at 24 to 72 hours post-Mtb infection to 
measure bacterial growth by CFU counting. Each data point represents arithmetic mean of 
triplicates ± SD. Three independent experiments were performed. 
(C) Cell viability of LNA-GapmeR transfected BMDMs at 4 hours post Mtb infection. Each data 





(D, E) Bax and Bcl2 mRNA expression measured by RT-qPCR from LNA-GapmeR transfected 
BMDMs treated with nutlin, rapamycin and Mtb infection for 24 hours. Each data point 
represents arithmetic mean of triplicates ± SD. Three independent experiments were 
performed. 
(F, I) Protein cytokine levels of IL-1β, IL-1a, IL-12 and IL-6 measured by ELISA from LNA-
GapmeR transfected BMDMs infected with Mtb for 24 hours. Each data point represents 
arithmetic mean of triplicates ± SD. Three independent experiments were performed. 
(J, K) Nitrite production measured by Griess reagent and arginase production from BMDMs 
LNA-GapmeR transfected and infected with Mtb for 24 hours. Data are represented as mean 
± SD of triplicates. Data are representative of three independent experiments.   *p<0.05, 
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Figure 4.3 IL7-AS functions independently of IL-7. (A-C) IL-7 mRNA expression measured by 
RT-qPCR on BMDMs transfected with LNA-IL7-AS and LNA-Control, non-stimulated and 
infected with Mtb. Each data point represents arithmetic mean of triplicates ± SD. Three 
independent experiments were performed. (D) BMDMs were transfected with LNA control 
and LNA IL7-AS, stimulated with IL-7 and infected with Mtb. Cells were lysed at 4 hours for 
uptake and at 24-72 hours post-Mtb infection to measure bacterial growth by CFU counting. 
Each data point represents arithmetic mean of triplicates ± SD. Three independent 
experiments were performed. (E, F) Protein cytokine levels of IL-7 measured by ELISA from 
LNA-GapmeR transfected BMDMs stimulated with IL-7 and infected with Mtb. Each data point 
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represents arithmetic mean of triplicates ± SD. Three independent experiments were 
performed. (G, H) Nitrite production measured by Griess reagent and arginase production 
from BMDMs LNA-GapmeR transfected pre-stimulated with IL-7 and infected with Mtb.  Data 
are represented as mean ± SD of triplicates. Data are representative of three independent 
experiments.  *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001, Student’s t-test. 
4.2.4 IL7-AS is induced in Mtb infected mice 
To examine the expression of IL7-AS in vivo, we collected whole lung from Mtb infected mice 
or naïve mice. IL7-AS was upregulated in mice infected with Mtb HN878 at 11 days post 
infection (Figure 4.4A).  We observed the upregulation of IL7-AS from whole lung infected 
with Mtb clinical isolate CDC1551 and with the virulent N0072 strain (Figure 4.4B). We 
examined the expression of IL-7 which was upregulated at day 11 and 21 post infection (Figure 
4.4C). We sorted by flow cytometry myeloid cells from Mtb infected lungs and naïve lungs 
and observed an upregulation of IL7-AS in interstitial recruiting macrophages, CD11DCs and 
neutrophils compared to the naïve cells (Figure 4.4D). As IL7-AS exhibits upregulated 
expression upon LPS stimulation in vitro, we challenged BALB/c mice with LPS at a sub-lethal 
dose (5 mg/kg mice weight; i.p.) for 4 and 8 hours and IL7-AS mRNA levels from various tissues 
were measured by RT-qPCR. LPS challenged mice had significantly elevated levels of IL7-AS in 
the peritoneal fluid, spleen and liver (Figure 4.4E-G). These results suggest that Mtb and LPS 
play a pivotal role in regulating IL7-AS both in vitro and in vivo.  
4.2.5 IL7-AS is induced in BMDMs exposed to TLR ligands and dependent on the Myd88 
signalling pathway 
We employed RT-qPCR to examine the kinetics of IL7-AS expression in BMDMs exposed to TLR 
ligands including LPS (TLR 4) and Pam3CSK4 (TLR2/1). The expression of IL7-AS was 
upregulated in both TLR ligands in a time dependent manner (Figure 4.5A-B). To evaluate the 
role of NF-κB and MAPK pathways we used selective pharmacological inhibitors for NF-κB  
(Bay11-7084), Erk1/2 (FR180204, extracellular signal-regulated kinase), Jnk (SP600125, c-Jun 
N-terminal kinase) and p38 (SB203580) to assess the functional consequences of inhibition of 
these pathways on IL7-AS expression. BMDMs stimulated with LPS in the presence of NF-κB 
and MAPK inhibitors showed a significant decrease in IL7-AS expression (Figure 4.5C-E). 
Similarly, BMDMs infected with Mtb in the absence of NF-κB and MAPK pathways had a 
significant reduction in IL7-AS expression (Figure4.5F-I). Next, we sought to measure the 
expression of IL7-AS in MYD88-/- BMDMs, since TLR4 signalling is dependent on MYD88 and 
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TRIFF [150]. IL7-AS expression was inhibited in MYD88-/- BMDMs at 4 and 24 hours post LPS 
stimulation (Figure 4.5J). Collectively, these results suggest that IL7-AS expression is regulated 
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Figure 4.4 IL7-AS is induced by Mtb infection and LPS challenge in vivo. (A) IL7-AS mRNA 
expression measured by RT-qPCR on whole lung from wild-type (WT) mice infected with Mtb 
HN878 (100 CFU/mouse) for 11 days. (B) IL7-AS mRNA expression measured by RT-qPCR on 
whole lung from wild-type mice infected with different Mtb strains (100 CFU/mouse). (C) IL-7 
mRNA expression measured by RT-qPCR on whole lung from wild type (WT) mice infected with 
Mtb HN878 (100 CFU/mouse) for 11 and 21 days. (D) IL7-AS mRNA expression measured by 
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RT-qPCR from myeloid sorted cells. (E) IL7-AS mRNA expression measured by RT-qPCR in 
peritoneal fluid, (F) spleen and (G) liver of WT mice challenged with LPS i.p.  (5 mg/kg/mice) 
for 4 and 8 hours; n=3 mice per group. Data are represented as arithmetic mean of triplicates ± SD. 
Data are presentative of one experiment. P values represented as, *P<0.05, **P<0.01, ****P<0.0001, 
Student’s t-test. 
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Figure 4.5 IL7-AS is induced in BMDMs exposed to TLR ligands and signals through Myd88. 
(A, B) RT-qPCR of IL7-AS mRNA expression in BMDMs stimulated with TLR-4 agonist LPS (100 
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ng/ml) and TLR-2 agonist Pam3Csk4 (100 ng/ml). Each data point represents arithmetic mean 
of triplicates ± SD. Three independent experiments were performed. 
(C-E) BMDMs were pre-treated for 1 hour  with selective pharmacological inhibitors for NF-ᴋB 
(Bay11-7084, 10 μM), p38 (SB203580, 5 μM), Jnk (SP600125, 10 µM) and  Erk1/2 (FR180204, 
10 μM), then activated by LPS stimulation (100 ng/ml) for 4 hours. Each data point represents 
arithmetic mean of triplicates ± SD. Three independent experiments were performed, or  
(F-I) Infected with Mtb HN878 for 4 hours. Expression of IL7-AS was detected by RT-qPCR. Data 
represents arithmetic mean of triplicates ± SD. Three independent experiments were 
performed. 
(J) IL7-AS mRNA expression measured by RT-qPCR from MYD88-/- BMDMs stimulated with LPS. 
Data represents arithmetic mean of triplicates ± SD. Three independent experiments were 
performed. *P<0.05, **P<0.01 and ***P<0.001, Student’s t-test. 
 
4.2.6 IL7-AS is induced in Mtb-infected human macrophages and active TB patients 
Because IL7-AS is conserved in humans as well, we observed its expression on human 
macrophages. We employed loss of function experiments using LNA GapmeRS to knockdown 
IL7-AS in human monocyte derived macrophages (MDMs). We confirmed knockdown 
efficiency of IL7-AS in unstimulated and LPS stimulated MDMs by RT-qPCR (Figure 4.6A-B). 
Knockdown of IL7-AS in human MDMs reduced Mtb intracellular growth at 24 and 48 hours 
post Mtb infection (Figure 4.6C). Knockdown of IL7-AS increased IL-6 protein levels measured 
by ELISA in unstimulated MDMs (Figure 4.6D). We examined IL7-AS and IL-7 expression from 
MDMs infected with Mtb HN878 ex vivo. Both IL7-AS and IL-7 were upregulated by Mtb 
infection in a time dependent manner (Figure4.6E-J). Finally, we collected PBMCs from healthy 
and active TB patients and re-stimulated with heat kill Mtb HN878. IL7-AS was upregulated in 
both active TB patients and re-stimulated PBMCs compared to healthy patients (Figure 4.6J-
K). Taken together, these results show that IL7-AS is upregulated in human macrophages and 
in TB patients suggesting a possible target for host-directed therapy. 
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Figure 4.6 IL7-AS is induced in Mtb-infected human macrophages and active TB patients. (A, 
B) Knockdown efficiency of IL7-AS by LNA IL7-AS in unstimulated and LPS stimulated human 
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MDMs analysed by RT-qPCR. Data point represents arithmetic mean of triplicates ± SD. Three 
independent experiments were performed. 
(C) MDMs were LNA GapmeR transfected for 48 hours and infected with Mtb HN878. Cells 
were lysed at 4h for uptake and at 24 and 48h post-Mtb infection to measure bacterial growth 
by CFU counting. Data represents arithmetic mean of triplicates ± SD. Three independent 
experiments were performed. 
(D) IL-6 protein production measured by ELISA on LNA-GapmeR transfected MDMs infected 
with Mtb HN878 for 24 hours. Data represents arithmetic mean of triplicates ± SD. Three 
independent experiments were performed. 
(E-G) RT-qPCR of IL7-AS mRNA expression on MDMs from healthy donors infected with Mtb 
HN878. Data represents arithmetic mean of triplicates ± SD. Three independent experiments 
were performed. 
(H, J) RT-qPCR of IL-7 mRNA expression on MDMs from healthy donors infected with Mtb 
(HN878). Data point represents arithmetic mean of triplicates ± SD. Three independent 
experiments were performed. 
(K, L) RT-qPCR of IL7-AS mRNA expression on re-stimulated PBMCs from healthy and active TB 
patients analysed by RT-qPCR. Data point represents arithmetic mean of triplicates ± SD. Data 
is representative of one experiment. P values represented as, *P<0.05, **P<0.01 and 
***P<0.001, Student’s t-test. 
 
4.3 Discussion  
Whilst the role of lncRNAs during Mtb infection remain unclear, there is growing research 
that indicates the association of lncRNAs with inflammation and regulation in the innate and 
adaptive immune response [12]. Using CAGE sequencing, we show for the first time 
differential lncRNA expression changes in polarised and Mtb infected mouse and human 
macrophages. This is very crucial since differential expression has always been the first step 
in identifying functional lncRNAs and has led to the identification of a number of lncRNAs that 
regulate inflammatory responses in immune cells including lincRNA-EPS [13], lincRNA-Cox2 
[14, 58], lncRNA-Mirt2 [16] in mice and THRIL [15], lnc-IL7R [43] and PACER [184] in humans 
to mention a few. The CAGE approach enabled us to identify a recently annotated lncRNA, 
IL7-AS, that is induced across multiple human and murine cell types. IL-7-AS is transcribed 
antisense to IL-7 gene. IL7-AS was first identified in human monocytes stimulated with LPS 
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using RNA sequencing [44]. Recently published studies have shown that IL7-AS is induced by 
LPS in human, mouse cell lines [31, 182]  and IL-1β stimulated pulmonary lung fibroblasts 
[179]. These studies suggest that IL7-AS may have a significant role in the innate immune 
system.  
In this study we observed no clear expression of IL7-AS in M0, M (IFN-γ) and M (IL-4/IL-13). 
Even though stimulation without Mtb showed no differential expression of IL7-AS, we did 
however observe a distinct upregulation of IL7-AS in Mtb infected macrophages. Because we 
did not see a distinct expression in M (IFN-γ) and M (IL-4/IL-13), we focused on M0 and Mtb 
infected macrophages for further functional validation. M1 (IFN-γ) macrophages are 
characterized by production of pro-inflammatory mediators such as nitric oxide (NO) usually 
associated with the control of infection [153]. In contrast, M2 (IL-4/IL-13) macrophages are 
immune modulators by secreting more ornithine and support a Th2-associated effector 
function [153].  Mtb is known to have evolved different strategies to interfere with M1 (IFN-
γ) polarization, neutralize microbicidal effectors to promote M2 (IL-4/IL-13) polarization 
resulting in its persistence and survival in the macrophages [153]. In this study, we 
demonstrate that knockdown of IL7-AS reduces intracellular Mtb growth in both mouse and 
human macrophages, suggesting that this lncRNA may be a target for Mtb growth. We sought 
to understand the mechanism behind the reduced Mtb growth by looking at inflammatory 
responses and apoptosis. Our data shows that knockdown of IL7-AS upregulated protein levels 
of IL-6, IL-1β, IL-1α and IL-12. This is similar to what was reported in murine, human, cancer 
cell lines [31, 182] and in lung fibroblasts [179]. These results suggest that IL7-AS is a negative 
regulator of inflammatory response. IL-1β and IL-1α have been linked to the control of Mtb 
infection [185]. However it has been reported that IL-6 produced by Mtb-infected 
macrophages can contribute to the inability of the host cell response to eradicate the infection 
[186] and Mtb is able to manipulate host IL-6 production so as to decrease type 1 interferon 
signalling which leads to disease progression [187]. 
M (IFN-γ) macrophages produce cytotoxic nitric oxide which is detrimental to Mtb growth [8]. 
Notably we observed increased nitrite production in the knockdown macrophages which 
contributed to the reduced intracellular growth.  It has been reported that apoptosis is able 
to control bacterial growth, however virulent strains of Mtb have been reported to inhibit the 
completion of apoptosis [156]. This is a virulence mechanism used by the pathogen to escape 
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host defences, and results in necrosis and persistent infection of the surrounding 
macrophages [156].  Our results suggest that apoptosis and increased inflammatory 
responses are used as a host defence mechanism to control Mtb infection. These data suggest 
that Mtb targets IL7-AS to increase Mtb intracellular growth by regulating inflammatory genes 
and apoptosis.  
IL-7 is known to be important for T and B cell development [188]. IL-7 which signals through 
the IL-7R plays a critical role in promoting T-cell survival by upregulating the expression of 
anti-apoptotic genes Bcl-2 and Mcl-1 [189]. Knockdown of IL7-AS did have a significant impact 
on IL-7 mRNA and protein levels indicating that IL7-AS controls the expression of IL-7 either 
directly in cis or indirectly in trans, given that IL7-AS knockdown also affects the expression of 
other inflammatory cytokines. IL-7 treatment in mice infected with LCMV is reported to 
increase cytokine production of IL-6, IL-1β, IL-1α, TNFα and CCL5 [190]. IL-7 was also shown 
to upregulate IL-8 mRNA expression in resting and human blood monocytes  stimulated with 
LPS, IL-1β and TNF-α [191]. Here, we show that the Mtb growth-promoting effect of IL7-AS is 
independent of its inhibition of IL-7 expression since stimulating BMDMs with IL-7 following 
IL7-AS knock down (50% efficiency) does not yield a synergistic further reduction of Mtb 
growth in BMDMs. The treatment of murine macrophages with IL-7 infected with Leishmania 
major significantly cleared leishmanial infection [192]. The survival of Mtb infected mice has 
been shown to be enhanced by IL-7 treatment in BALB/c mice 3 weeks post infection [193]. 
This is like our results where we observed reduced intracellular Mtb growth in BMDMs 
treated with IL-7 then infected with Mtb.  
TLR 2 and TLR 4 are known to play pivotal roles in the induction of immune response to many 
different infectious disease including Mycobacterium species [194].  TLR 2 is known to 
mediate Mtb-induced TNF-α expression,  while TLR 4 plays significant role in the resistance to 
Mtb infection [194]. The activation of MAPK pathways leads to the induction of transcription 
factors including NF-Kb [195]. All three MAPK pathways are activated post Mtb infection and 
linked to disease pathogenesis [196]. Promoter binding of transcription factors may regulate 
lncRNA gene expression. In this study, we show that IL7-AS is induced by both TLR 2 and TLR 
4 and dependent on the NF-ᴋB and MAPK signalling pathways. Many lncRNAs have been 
shown to be dependent on the NF-ᴋB and MAPK pathways including p38, JNK and Erk1/2 [13]. 
Previous studies have shown that the promoter binding of the NF-kB p65 subunit and MAPK 
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c-Jun subunit are both needed for the trans-activation of IL7-AS in macrophages and in 
epithelial cells post-LPS stimulation [182].  
IL7-AS has been reported to be conserved in both mouse and human and induced in various 
cell types [31]. Our study revealed that knockdown of IL7-AS prompted reduction of Mtb 
intracellular growth and increased expression of IL-6 in human macrophages. This is similar 
to what was observed in our mouse data. These results imply that IL7-AS may be an important 
regulator in innate immune response. Additionally, we observed an upregulation of IL7-AS 
and IL-7 in human MDMs infected with Mtb and in PBMCs from active TB patients or re-
stimulated with heat killed Mtb. Therefore, IL7-AS is a key factor not only in inflammatory 
responses but also in controlling Mtb infection progression.  
In conclusion we functionally characterized IL7-AS, which is conserved in both mouse and 
human. IL7-AS is shown to be a target for Mtb growth and persistence by regulating 
inflammatory responses. IL7-AS is induced by Mtb and LPS and depends on the NF-ᴋB and 
MAPK pathways. An experiment where we assess the role of IL7-AS in the pathogenesis of TB 
in vivo is crucial. The role of IL7-AS in TB pathogenesis and inflammatory gene response is very 














Chapter 5: General discussion and conclusions  
5.1 Aim for chapter 3 
The aim of this thesis was to functionally validate lincRNA-MIR99AHG and its interacting 
partner in polarized and/or Mtb-infected macrophages using chemically engineered 
antisense oligonucleotides (GapmeRs). To carry out this investigation, we performed 
knockdown experiments of MIR99AHG in mice and human macrophages as well in vivo using 
antisense oligonucleotides. 
5.2 Summary of results from Chapter 3 
Our work on the functional role of MIR99AHG was presented in Chapter 3. Following 
stimulation and Mtb infection in M1 (IFNγ) and M2 (IL-4/IL-13) macrophages, we observed an 
upregulation of MIR99AHG in M2 (IL-4/IL-13) macrophages and a downregulation upon Mtb 
infection. These results suggest that MIR99AHG is induced in M2 (IL-4/IL-13) macropahges 
and inhibited by Mtb. Knockdown of MIR99AHG in both mouse and human macrophages 
resulted in reduced intracellular Mtb growth and proinflammatory genes such as IL-6 and IL-
1β. The production of nitrite and CD86 was reduced compared to the control.  Knockdown of 
MIR99AHG led to increased apoptosis measured by flow cytometry suggesting that apoptosis 
and not proinflammatory gene induction is the mechanism underlying the reduced Mtb 
growth. MIR99AHG was also confirmed to have a cis-regulatory effect on the nearby gene, 
Cxadr. To investigate whether the beneficial effects of MIR99AHG suppression could be 
translated into a host-directed therapy (HDT), we used antisense oligonucleotides known as 
LNA GapmeRs to knockdown (KD) MIR99AHG in a mouse Mtb infection model and tested its 
prophylactic efficacy. At 3 weeks post infection there was reduced mycobacterial load in the 
lungs and spleen of MIR99AHG KD mice compared to the control group. Lung inflammation 
measured by alveolar spaces was significantly increased in MIR99AHG KD mice. We also 
observed reduced neutrophil influx, iNOS and T cell recruitment in MIR99AHG KD mice 
compared to the control group. We did however notice increased apoptosis in Mtb infected 
mice treated with MIR99AHG in vivo as also measured in human and mouse macrophages in 
vitro post Mtb infection. Myeloid cell sorting by flow cytometry showed reduced IL-6, IL-1β, 
IL-10, TGFβ, Nos2, Arg1, Mrc1 and Ym1 in MIR99AHG KD mice compared to the control group. 
Collectively, these results suggest that MIR99AHG is a target for Mtb for contribution in TB 




5.3 Studies contributing to generation of the hypothesis in Chapter 3 
Our work followed on from two pivotal studies on the transcriptional landscape of Mtb in M1 
(IFNγ) and M2 (IL-4/IL-13) macrophages [147] and redefining the transcriptional regulatory 
dynamics of M1 (IFNγ) and M2 (IL-4/IL-13) macrophages by CAGE [142]. Briefly, Roy et al. 
[142, 147] identified novel motifs, transcription factors, protein coding and lncRNA genes 
differentially expressed in M1 (IFNy), M2 (IL-4/IL-13) and Mtb infected macrophages. From 
the differentially expressed lncRNAs identified from Roy et al.[147], we functionally validated 
MIR99AHG with in vivo and in vitro mouse experiments. The findings reported in our study 
show the novel functional role of MIR99AHG in M2 (IL-4/IL-13) macrophages and during Mtb 
infection. Previously, functionally validated lncRNAs during Mtb infection have provided an 
insight into how Mtb is able to target both miRNAs and lncRNAs for persistence within 
macrophages [64, 66, 68, 100]. LncRNA-MEG3 was reported to eradicate M. bovis BCG in 
macrophages via autophagy [68]. Recently our group showed that miR-143 and miR-365 are 
both upregulated in M2 (IL-4/IL-13) and in Mtb infected macrophages. They target c-Maf, 
Bach-1 and Elmo-1 to reduce intracellular Mtb growth [100]. MicroRNA-27a was reported to 
reduce the intracellular survival of Mtb through controlling Ca2+-associated autophagy [197]. 
Our current study also shows similar results where knockdown of MIR99AHG reduced 
mycobacterial load in macrophages and in mice due to increased apoptosis. The comparison 
of our results to other studies is hindered due to very limited research performed on the 
functional validation of lncRNAs in polarised and/or Mtb infected macrophages.  
5.4 Conclusions to Chapter 3 
Overall, we showed that lincRNA-MIR99AHG is abundantly expressed in IL-4/IL-13 polarized 
mouse and human macrophages and downregulated in Mtb infected macrophages. LincRNA-
MIR99AHG was shown to regulate inflammatory gene expression in macrophages stimulated 
with IL-4/IL-13 and infected with Mtb. Knockdown of MIR99AHG in Mtb-infected mice 
reduced the mycobacterial burden in lung and spleen as well as in macrophages in vitro. We 
report that MIR99AHG regulates the expression of its nearby gene, Cxadr and mediates these 
functions by interaction with the protein-coding gene hnRNPB2/A1. We show that MIR99AHG 
is downregulated in PBMCs of active TB patients. We propose a model whereby IL-4/IL-13 
78 
 
induces the upregulation of MIR99AHG which is then targeted by Mtb for intracellular survival 
in macrophages. 
5.5 Aim for chapter 4 
The aim of this study was to functionally validate lncRNA IL7-AS in polarized and/or Mtb-
infected macrophages using chemically engineered antisense oligonucleotides (GapmeRs). To 
accomplish this investigation, we performed knockdown experiments of IL7-AS in mice and 
human macrophages using LNA antisense oligonucleotides known as GapmeRs.  
5.6 Summary of results from chapter 4 
Our work on the functional role of IL7-AS was presented in Chapter 4. There was no distinct 
differential expression of IL7-AS in M1 (IFNy) and M2 (IL-4/IL-13) macrophages. However, IL7-
AS was noticeably upregulated by Mtb infection in both M1 (IFNγ) and M2 (IL-4/IL-13) 
macrophages. These results suggest that IL7-AS is induced by Mtb. Following knockdown of 
IL7-AS in mouse and human macrophages, we observed reduced intracellular Mtb growth. 
The reduction in bacterial load was due to increased production of IL-6, IL-12, IL-1α and IL-1β. 
Nitrite production was induced in LNA GapmeR treated BMDMs while we observed no 
significant difference in arginase production compared to the control. IL7-AS overlaps with 
the promoter of IL-7 in antisense. We show on this study that knockdown of IL7-AS enhances 
IL-7 expression however, IL7-AS functions independently of IL-7 for the promotion of Mtb 
growth. LPS challenge in mice showed that IL7-AS is induced in the peritoneal fluid, spleen 
and liver. IL7-AS is induced by TLR 4 and 2 ligands. IL7-AS expression was inhibited the absence 
of NF-κB, MAPK and Myd88 signalling pathways. These findings suggest that IL7-AS is 
dependent on these signalling pathways. IL7-AS is conserved in humans as well and our results 
show that IL7-AS is upregulated in human macrophages post Mtb infection and in PBMCs from 
active TB patients compared to healthy individuals. 
5.7 Studies contributing to generation of the hypothesis in Chapter 4 
As previously mentioned above, our work follows the two pivotal studies from Roy et al. [142, 
147]. IL7-AS was chosen to be functionally validated because it is upregulated by Mtb and has 
not yet been studied in an Mtb disease model. We functionally validated IL7-AS with in vitro 
mouse experiments. Previous studies have shown that IL7-AS is induced by LPS or IL-1β across 
different cell types and regulates the production of IL-6 [31]. In our study we also show that 
IL7-AS is induced by LPS and Mtb infection. Findings presented by Liu et al. [182] showed that 
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IL7-AS promote the expression of proinflammatory genes such as CCL2, CCL5, CCL7 and IL-6 
in cells stimulated with LPS. In our study we also show similar results in the induction of IL-6, 
IL-1α and IL-1β in mouse and human macrophages stimulated with LPS or infected with Mtb. 
A mechanism was revealed whereby IL7-AS was reported to be dependent on the NF-κB and 
MAPK signalling pathways [182]. These results are supported by the findings from our study. 
The authors further show that IL7-AS interacts with p300 to regulate histone acetylation at 
the promoter regions of their target genes [182]. Further experiments in vivo need to be 
performed to strengthen our findings. It would be interesting to perform an in vivo study 
where we treat mice with IL7-AS ASOs and then infect with Mtb or maybe generate a 
knockout mouse. This would make our story more compelling and make IL7-AS a potential 
target for host directed therapy (HDT). Currently, there are no in vivo studies on the functional 
role of IL7-AS during Mtb infection or any other disease model.    
5.8 Conclusion to Chapter 4 
Overall, we show that IL7-AS is induced by Mtb and LPS. It is an important regulator of 
proinflammatory genes and a target for Mtb growth. We also show that IL7-AS expression is 
dependent on NF-κB, MAPK and Myd88 pathways. Altogether, IL7-AS could be a potential 
target for HDT. 
5.9 Relevance of studies and future work 
Tuberculosis continues to be the leading infectious disease in the world killing more than 1.5 
million people per year [1]. South Africa is one of the countries in the world with the highest 
burden for TB, TB/HIV and MDR-TB [1]. The current prevention for TB is through the 
vaccination of children with the bacille Calmette-Guerin (BCG) vaccine [1]. The BCG vaccine 
does not always protect adults from getting infected with TB. There is increasing drug 
susceptibility for first line drugs and along with this increasing chances for developing MDR-
TB and XDR-TB [1]. New anti-TB therapies that target host factors are needed. Long noncoding 
RNAs are potential host-derived drug targets which can be used for diagnosing and/or 
treating tuberculosis. Therapeutics that directly target lncRNAs are promising for many 
diseases and disorders. Our study was the first line of work which inhibited these lncRNAs in 
mouse models during Mtb infection. Our results do show these lncRNAs could potentially be 
used as therapeutics in TB. The next step would be to check the efficacy of these ASOs in a 
clinical trial.  As mentioned previously in the literature review, there is quite a few ASOs that 
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have been approved by the FDA and including the ASOs that are currently in clinical trials for 
various diseases. Our research group will soon start a clinical trial on simvastatin as host-
directed therapy for TB. It is our goal that one of these lncRNAs will one day be involved in a 
clinical trial as an anti-TB therapeutic. 
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